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SUMMARY
In this study, we investigated the immune response of 
patients with Ankylosing Spondylitis (AS) and looked for 
evidence to support the proposal that AS is a form of 
reactive arthritis in which Klebsiella or other 
Enterobacteriaceae play a role.
Immunoglobulin levels in patients' sera were measured. 
Using the laboratory parameters erythrocyte sedimentation 
rate (ESR) and C-reactive protein (CRP) levels as 
indicators of disease activity, it was found that patients 
with active disease had considerably higher levels of IgA 
and IgG than patients with inactive disease or controls. 
This suggests that these immunoglobulin levels could be 
another useful indicator of disease activity and they were 
therefore taken into account in all subsequent patient 
studies.
It has been suggested that these high serum immunoglobulin 
levels indicate an ongoing immune response to antigen in 
patients with active disease, but such marked elevations 
are more likely to be accounted for by non-specific 
mechanisms. We had hoped to investigate any cellular basis 
for this by co-culturing AS and normal lymphocytes. 
However, in vitro immunoglobulin production by peripheral 
blood lymphocytes (PBLs) did not reflect the serum 
studies : we were unable to demonstrate any abnormality in 
the production of immunoglobulin by patients' lymphocytes.
The possibility of involvement of Enterobacteriaceae in AS 
was studied by measuring the levels of specific antibody in 
patients' sera to sonicated preparations of several 
bacteria. An enzyme -linked immunosorbent assay (ELISA) was 
used. When total antibodies were measured (i.e. all 
immunoglobulin classes), no differences were found between 
patients and controls. However, when antibodies of the
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IgA class only were studied, patients were found to have 
elevated antibody levels to Klebsiella and the three 
arthritogenic bacteria Salmonella, Shigella and Yersinia. 
This was not simply a result of the general elevation in 
serum IgA found in patients since normal levels of IgA 
antibodies to E .coli and Proteus were found. Using SDS- 
polyacrylamide gel electrophoresis (PAGE) and 
immunoblotting, an attempt was then made to identify any 
abnormality in the level of serum antibodies to individual 
Klebsiella proteins. No obvious difference was found in 
the blotting pattern of sera from controls, patients with 
inactive disease and patients with active disease.
Since Klebsiella and the other bacteria implicated in AS 
are found in the gut, a study of the gut immune response 
should provide a better indication of whether antigenic 
stimulation by such bacteria has occurred. We studied
patients' saliva, the only gastrointestinal secretion 
readily available. In an ELISA, neither patients as a 
whole nor the active disease group had high levels of total 
salivary IgA or IgA antibodies to formalin-killed or 
sonicated Klebsiella or Yersinia.
If, as it has been suggested, the immune response to
Enterobacteriaceae plays a pathogenic role in the disease,
we would expect to find evidence for this immune response
at the site of inflammation - the joints. We measured
antibodies to sonicated and formalin-killed preparations of
Klebsiella, Salmonella, Shigella and Yersinia in synovial 
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fluids. These antibody levels were no higher in AS 
patients than in patients with Rheumatoid Arthritis or 
other inflammatory joint diseases. Moreover, the antibody 
response to these four bacteria was similar to that found 
to E .coli, a bacterium which has not been implicated in the 
seronegative spondyloarthropathies. Further studies using 
immunoblotting revealed no difference between AS and other 
patients in the level of synovial fluid antibodies to 
individual Klebsiella proteins .
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In the known reactive arthritides, lymphocytes from the 
joint demonstrate an elevated cellular immune response to 
the causative organism. We therefore measured the in vitro 
proliferative response to Klebsiella of AS synovial T- 
cells. This was not significantly different from the 
response of synovial lymphocytes from patients with other 
diseases.
The humoral immune response in AS was further studied by 
measuring the levels of circulating immune complexes (CIC) 
in patients' sera. Using a Raji assay, patients were found 
to have elevated levels of IgG-CIC which were associated 
with active disease while an assay based on polyethylene 
glycol (PEG) precipitation and radial immunodiffusion 
revealed a difference between patients and controls which 
was independent of disease avtivity. All patients had 
normal serum levels of IgM-CIC. Significant levels of both 
IgG- and IgM- immune complexes were found in AS synovial 
fluids. These immune complexes may have no pathogenic 
relevance but they could be useful in the identification of 
any environmental factors associated with the disease. We 
concentrated immune complexes from serum and synovial 
fluids by PEG precipitation; using SDS-PAGE and 
immunoblotting, we studied the reactivity of anti- 
Klebsiella antisera to proteins within these complexes. No 
evidence for the presence of Klebsiella antigens was found.
As well as a study of the immune response to 
Enterobacteriaceae in AS, the presence of the bacteria 
themselves was investigated using rectal swabs. Klebsiella 
was isolated from only 17% of AS patients and apart from 
E . coli, no other bacterium was found in more than 10% of 
cases.
The main theory proposed to explain the involvement of 
Enterobacteriaceae in AS is that of molecular mimicry which 
is dependent on an immunological cross-reaction between 
these bacteria and the B27 antigen. We investigated this 
by measuring the ability of anti-Klebsiella antisera to
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bind to B27-positive lymphocytes in an immunofluorescence 
assay and the ability of anti-B27 tissue-typing sera to 
bind to various Enterobacteriaceae in an ELISA. No
evidence for cross-reactivity was found. In addition, we 
looked at a six amino acid sequence which is found to be 
shared by the B27 antigen and a Klebsiella protein. We 
looked for antibodies in patients’ sera reactive to a 
synthetic peptide representing this sequence but no 
significant levels of such antibodies were found.
In conclusion, our studies lend little support to the 
proposal that AS is a form of reactive arthritis in which 
Klebsiella or other Enterobacteriaceae play a pathogenic 
role.
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CHAPTER 1
INTRODUCTION
Ankylosing Spondylitis (AS) is a chronic inflammatory 
joint disease of unknown aetiology which primarily affects 
the spine and sacroiliac joint. The name is derived from 
the Greek words "ankylos" which means bent and 
"spondylos" which means vertebra. Within the joint, 
repeated bouts of inflammation of the entheses (bone- 
ligament junctions) occur and the lesions are repaired by 
deposition of fibrous tissue and bone, leading to 
immobilisation of the joint. The disease, which is 
predominantly found in males, usually has an insidious 
onset in early adulthood. The most common clinical 
features are lower back pain and morning stiffness. As 
the disease progresses, the entire spine can become stiff 
and the patient loses normal posture, often developing a 
forward stoop of the neck (kyphosis). Figure I shows a 
patient with severe AS with classical kyphosis. Other 
joints, such as hips, shoulders and knees can be involved 
in up to 35% of patients (1) and in some cases, 
inflammation of extra-articular tissue such as the eyes, 
heart and lungs can occur (2).
AS has probably existed since ancient times since it has 
been documented in the remains of Egyptian mummies (3).. but 
the first accurate account of the disease is thought to be 
that of Bernard Connor in 1695 (cited by Blumberg (4)); and } 
it was not until the 1930s that the full clinical picture 
of AS emerged.
Since the start of this century, a number of theories on 
the aetiology of AS have been proposed and a variety of 
treatments have been used. At the turn of the century, an 
abnormal reaction to trauma was proposed as the cause of 
the disease (5). So too was focal sepsis (6,7) which led 
to the removal of teeth, tonsils, appendices and even
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colons from many unfortunate patients. Some patients 
underwent parathyroidectomy in the 1930s because of the 
proposal that high calcium levels were responsible for the 
disease (8). In the 1 950s, treatment with deep X-ray 
therapy had a considerable degree of success although how 
it worked is not clear and the widespread use of such 
treatment ceased after it was discovered that it conferred 
a high risk of leukaemia (9) . Currently, there is no 
definitive treatment for AS. Management is directed at 
the suppression of pain and stiffness with simple 
analgesics and non-steroidal anti-inflammatory drugs 
(NSAIDs) such as indomethacin and phenylbutazone, and at 
the establishment of an exercise programme to prevent or 
minimise deformities of the spine.
Many population and family studies have been carried out 
and by the 1950s, it was well established that AS tends to 
aggregate within families. Stretcher et a l . (10) found
that the disease was 30 times more prevalent among 
relatives of AS patients than among controls. This has 
been supported by recent studies (11,12) and suggests that 
the disease is under genetic control. This was supported 
by the landmark discovery in 1973 of the association 
between AS and the human leucocyte antigen (HLA) B27 -
simultaneously reported by Brewerton et a l . (13) in the UK
and Schlosstein et a l . (14) in the USA.
HLA antigens are cell-surface glycoproteins which are the 
products of a group of genes known as the major 
histocompatability complex (MHC). The class I antigens 
HLA-A, -B and -C are 44kD transmembrane proteins which are 
found on the surface of most nucleated cells, non-
covalently linked to the 12kD glycoprotein beta-2-
microglobulin. Class II or HLA-D/DR antigens consist of 
two polypeptide chains of 28kD and 32kD and are found 
mainly on B -lymphocytes and antigen-presenting cells. HLA 
antigens have several important roles in the immune
response. D/DR antigens are thought to be the analogues 
of la antigens in mice which are involved in antigen
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presentation : they interact with foreign antigens to form 
an epitope recognised by helper T-lymphocytes (15). 
Similarly, class I antigens are involved in the 
recognition of antigen by Ts or cytotoxic T-cells.
A large number of diseases, involving every medical 
speciality, are associated with particular HLA alleles
(16). The list of HLA-disease associations is rapidly
expanding, partly due to the increasing availability and 
specificity of tissue - typing techniques. The largest 
group is associated with D/DR antigens and includes the 
putatively autoimmune diseases Rheumatoid Arthritis (RA) , 
Systemic Lupus Erythematosis (SLE), Myasthenia Gravis and 
Graves' Disease (16). The remaining group is associated 
with class I, mainly HLA-B antigens, and includes AS. In
most cases, the role played by the HLA antigen is not
known.
The association between B27 and AS is the strongest HLA- 
disease association known : as many as 95% of Caucasoids
with AS are B27-positive while this antigen is found in 
less than 8% of healthy Caucasoids (13,14). The
association holds true for all racial, geographical and 
ethnic groups studied although in some groups, the 
percentage of patients with B27 is considerably lower than 
95% (17).
Two main theories have been put forward to explain the 
relationship between AS and B27. The two gene theory, 
first proposed by McDevitt and Bodmer (18), postulates 
that the B27 gene is not itself involved in AS but is in 
linkage disequilibrium with another gene which is 
responsible for the disease. Linkage disequilibrium 
between genes is not uncommon : the HLA association of
congenital adrenal hyperplasia can be explained by linkage 
of the MHC with the gene for 21 - hydroxylase enzyme (19). 
Similarly, idiopathic haemachromatosis is related to a 
defect in a gene invoved in iron metabolism and this gene 
is closely linked to the MHC (20).
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It has been proposed (18) that the B27 gene is linked to a 
D/DR gene which acts as an immune response gene. In this 
way, an abnormal immune response to an environmental agent 
such as an infectious organism could account for 
development of AS in B27+ individuals. However, studies 
of HLA-D/DR alleles show no correlation with AS (21, 22)
and no mechanism has been proposed to explain how any 
other linked gene might mediate the disease. Moreover, 
despite an extensive search, there is no evidence of 
recombinant families where dissociation of AS from the B27 
gene has occurred (23) . In view of these findings, the 
two gene theory is unlikely to explain the association of 
AS with B27 and the one gene theory has now gained quite 
widespread acceptance.
The one gene theory postulates that the B27 gene is 
directly involved in precipitating the disease and two 
main mechanisms for this have been proposed. In the
receptor theory, first proposed by Seager et a l . (24), the
B27 antigen acts as a receptor for some disease - inducing 
factor. In the molecular mimicry theory (25), it is 
suggested that the B27 antigen cross-reacts with an
environmental factor such as a micro-organism and this
leads to an aberrant immune response. This response could 
be specific tolerance to the factor since the immune 
system is often unresponsive to antigens which resemble 
"self". In this way, a micro-organism could escape normal 
immune mechanisms and be allowed to persist in a B27+ host 
and cause tissue damage. Alternatively, this
environmental factor could induce a positive immune 
response which also recognises the cross-reactive B27
antigen. Normal tolerance to B27 may then be overridden, 
resulting in autoimmunity. Such a mechanism operates in 
Rheumatic Fever where cross-reaction between Streptococcal 
cell walls and human cardiac tissue leads to an autoimmune 
response (26).
Evidence that environmental factors as well as genetic 
factors are involved in AS comes from the discordance
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observed between monozygotic twins (27, 28) and the fact
that less than 2% of B27+ individuals develop the disease
(29, 11). As far as it is known, there is no difference
in the B27 antigens of AS patients and normal B27+ 
individuals (30).
It has long been suspected that the environmental factors 
associated with AS may be bacteria. AS is one of a group 
of arthritic diseases known as the seronegative 
spondyloarthropathies (which are "negative" for rheumatoid 
factor) and these include the reactive arthritides. 
Reactive arthritis (ReA) is normally an acute arthritis 
which has a well established association with an infection 
with an enteric or sexually-transmitted micro-organism
such as Salmonella (31), Yersinia (32), Shigella (33) or 
Chlamydia (34). The role played by these micro-organisms 
is not clear and all attempts to culture them from the
joints have failed (35, 36) suggesting that local
infection is not the cause of the joint inflammation. 
These reactive arthritides share certain features with AS: 
60-80% of patients with ReA possess the HLA-B27 antigen 
(37); the peripheral arthritis of AS and ReA are 
histologically similar; Reiter's Syndrome (RS) is a 
chronic form of ReA which is associated with urethritis 
and conjunctivitis, and around 30% of patients with RS 
develop spondylitis (38). Many investigators therefore
believe that AS may also be a reactive arthritis, 
triggered by an infectious agent (39).
To investigate the possibility that an infectious organism 
could induce AS through molecular mimicry with the B27 
antigen, Ebringer et a l . (25) raised antisera to B27 +
lymphocytes and tested their ability to interact with a 
range of bacteria. By immunodiffusion, the antisera were 
found to react with isolates of Klebsiella, Enterobacter 
and Yersinia. This reactivity was later confirmed using 
other techniques such as haemagglutination and
radiobinding assays (40). The same group then reported
that AS patients have a higher than normal rate of faecal
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carriage of Klebsiella pneumoniae, particularly during 
phases of active disease (41). These studies led to the 
proposal that Enterobacteriaceae such as Klebsiella play a 
pathogenic role in AS through molecular mimicry with the 
B27 antigen.
In the last decade, a large number of studies have been 
carried out in an attempt to confirm these findings and to 
look for further evidence for the role of 
Enterobacteriaceae in AS.
The possibility of cross-reaction between Klebsiella and 
B27 and has been extensively studied. Ebringer's group 
have found evidence for this by using a number of 
techniques to demonstrate the ability of rabbit and human 
anti-B27 antisera to interact with Klebsiella (25, 42) and 
the ability of anti-Klebsiella antisera to interact with 
B27+ cells (25, 40) . Some further evidence has come from
studies with monoclonal antibodies (43, 44) and one group
has recently found a possible molecular basis for such 
•cross-reaction by identifying a six amino acid sequence 
shared by the B27 antigen and a Klebsiella protein (45).
An Australian group led by Geczy (46) have repeatedly 
demonstrated that anti-Klebsiella antisera react with B27+ 
cells from AS patients but not from healthy donors and 
they propose that AS patients have a Klebsiella-derived 
product on the surface of their cells in association with 
the B27 antigen. However, several investigators have been 
unable to confirm the findings of either Ebringer's or 
Geczy's group or to find any evidence for cross-reaction 
between Klebsiella and the B27+ cells of AS patients (47, 
48, 49, 50) .
In their more recent studies, Ebringer et a l . (51, 52)
have been able to confirm their early report of high 
faecal carriage of Klebsiella in AS patients and Kuberski 
et a l . (53) also demonstrated that Klebsiella could be
isolated more frequently from patients with active disease 
than from controls. Several groups, however, have failed
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to find an association between Klebsiella carriage and 
either the presence or activity of AS (54, 55, 56).
AS patients have been found to have elevated levels of 
immunoglobulins, particularly IgA (57, 58, 59, 60). Since 
the majority of IgA is derived from mucosal surfaces such 
as the gut (61), it is suggested that this indicates 
antigenic stimulation at such sites and thus provides 
further support for the involvement of gut bacteria in the 
disease (57, 62).
The possibility of an immune response to bacteria in AS 
has been studied more directly. It has been shown that 
patients with ReA have high levels of serum antibodies 
which react with the organism that precipitated the 
disease (63, 64, 65) and several investigators have
measured antibodies to Klebsiella and other 
Enterobacteriaceae in AS patients. Higher than normal 
levels of IgA antibodies to Klebsiella (66, 67, 39) and
Yersinia (68, 69) have been detected in the sera of
patients with active disease and one study demonstrated 
elevated levels of anti-Klebsiella antibodies in patients' 
saliva (65).
Further evidence for an ongoing humoral immune response in 
AS comes from several reports that patients have high 
levels of circulating immune complexes (CIC) (70, 71, *12,
73, 74, 75) . These complexes may or may not have any
pathogenic relevance but they could be of great value in 
the identification of any aetiological agent. One study 
(76) demonstrated that CIC from AS patients cross-react 
with each other but not with CIC from other disease groups 
which suggests that the complexes contain disease - specific 
antigens. So far, however, little attempt has been made 
to identify the antigens within these complexes.
The possibilty of a role of the cellular immune response 
in AS has also been studied. The in vitro proliferative 
response of patients' peripheral blood lymphocytes (PBLs) 
have been measured but no consistent abnormality has been
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demonstrated in either the non-specific response to 
mitogen (77, 78, 79) or the specific response to bacterial
antigens (24, 80, 79).
As in many current studies in AS, the main aim of our 
project was to look for evidence which might support the 
proposal that Klebsiella or other Enterobacteriaceae play 
a role in the disease. This involved studies of patients' 
humoral and cellular immune response to bacteria 
(particularly in the joint), an attempt to demonstrate 
bacterial antigens within immune complexes and a study of 
the immunological cross-reactivity between B27 and 
Klebsiella.
Note on the Assessment of Disease Activity
There are no internationally recognised criteria for the 
assessment of disease activity in patients with AS. A 
variety of clinical measurements are used including pain, 
morning stiffness, physical measurements of mobility, the 
level of non-steroidal anti-inflammatory drugs (NSAIDs) 
required and the presence of peripheral arthritis. The 
main laboratory parameters used are the erythrocyte 
sedimentation rate (ESR) and the serum levels of C- 
reactive protein (CRP) and immunoglobulins. The use of 
different criteria by different investigators may explain 
some of the conflicting findings in AS.
In many studies, disease activity is assessed using only 
the laboratory measurements ESR or CRP or a combination of 
these (57, 67, 73). ESR and CRP serve as non-specific
indicators of inflammation and are useful in assessing 
disease activity in RA (81). However, although AS 
patients with clinically active disease do tend to have 
higher ESR and CRP levels than those with inactive disease 
(57, 82), the serial studies of Scott et a l . (83) suggest
that these measurements are not very reliable as 
indicators of disease activity in AS. This is supported 
by the findings of Ogryzlo (1). Moreover, Laurent et a l .
(84) reported that ESR correlates better with the 
peripheral arthritis of AS than the spondylitis.
Clinical measurements can be subjective and it is not 
always clear whether pain/immmobility is due to acute 
inflammation or to joint damage caused by previous 
inflammatory attacks.
Rather than relying on any one criterion to assess disease 
activity in our studies, medical staff in our group 
designed a point system which took several clinical and 
laboratory factors into account. (See " Point System for 
Assessment of Disease Activity ", Appendix A.) These
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included morning stiffness, NSAID requirements, the 
presence of peripheral arthritis, and ESR and CRP. IgA 
and IgG levels were also included because of the finding 
by us and other groups that high levels of these 
immunoglobulins are associated with high ESR and CRP or 
clinically active disease (57,59,60, and see Chapter 2 of 
this thesis). These immunoglobulin levels were considered 
to be elevated when they were above the normal range 
( > 15mg/ml IgG ; > 4.5mg/ml IgA).
This point system for assessing disease activity was used 
in all our studies unless otherwise stated. All patients 
were diagnosed as having AS using the New York criteria
(85) .
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CHAPTER 2
IMMUNOGLOBULIN STUPXES
2.1 Introduction
An early study of serum immunoglobulins using 
immunoelectrophoresis found broader and more intense IgM 
precipitation lines in sera of AS patients than in normal 
control sera (86) . More recently, Veys et a l . (87) used a
linear plate immunodiffusion technique to demonstrate 
elevated levels of all three major classes of 
immunoglobulin in patients’ sera. In this study, no 
correlation was found between immunoglobulin levels and 
any of the four criteria for disease activity used (ESR, 
CRP, subjective complaints and scanning of joints).
Several groups, however, have demonstrated differences in 
serum IgA levels between patients with active disease and 
those with inactive disease using a number of different 
criteria for disease activity. Cowling et a l . (57) found
elevated IgA in patients with an ESR above 15mm/hr or a 
CRP above 15 iig/ml and similar findings were reported by 
Calguneri et a l . (58) . Hicking et a l . (59) defined
patients with active disease as those with an ESR above 
30mm/hr, early morning stiffness and a necessity for 
increased doses of non-steroidal anti-inflammatory drugs 
(NSAIDs). Such patients were found to have higher serum 
IgA levels than patients with inactive disease. In a 
longitudinal study (60), it was found that serum IgA 
correlated with a composite index of disease activity 
which took into account chest expansion, lumbar flexion 
index, morning stiffness and spinal pain. The author
concluded that regular measurement of IgA would be useful 
in the assessment of disease activity. These studies all 
measured immunoglobulins by radial immunodiffusion. 
Similar high IgA levels were found in AS patients with
1 1
active disease when an enzyme linked immunosorbent assay 
(ELISA) was used (52). Recently, Collado et a l . (88) and
Mackiewicz et a l . (62) have both demonstrated a
statistically significant correlation between IgA and CRP 
levels in AS.
As well as IgA, serum IgG and IgM levels have been 
studied. Several groups have shown increased
concentrations of IgG in AS patients (78, 87, 89, 90) and 
some have found this to be associated with active disease. 
(58,59,60). No direct correlation between this class of 
immunoglobulin and any of the laboratory parameters of 
disease activity has been reported. IgM appears to be 
normal in AS. Only one study (87) found high levels of 
IgM in patient sera and this was not associated with 
active disease.
One group sought to determine whether the serum studies 
were reflected by immunoglobulin production by patients' 
peripheral blood lymphocytes (PBLs) in vitro (91). They 
found no difference in IgA or IgG production between 
patient and control cells in unstimulated or pokeweed 
mitogen (PWM)- stimulated cultures. PWM is one of a group 
of lectins which non-specifically activate lymphocytes. 
One significant finding was, however, a low IgM response 
to PWM. In a study designed to measure specific 
antibodies to Enterobacteriaceae and B27 in mitogen- 
stimulated cultures, Cavender et a l . (92) found no
abnormality in the secretion of total IgA, IgG or IgM by 
patient's lymphocytes (although only a small number of 
patients were used in this study).
Most studies of immunoglobulins in AS have looked for 
abnormalities in serum levels. However, because of the 
suspected association of the disease with gut bacteria and 
the fact that the serum immunoglobulin most consistently 
raised in AS is IgA (a class of immunoglobulin normally 
associated with antigenic stimulation at mucosal sites), 
it may be more useful to look at gastrointestinal
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secretions which contain antibodies of the gut mucosal 
immune system. Clearly, it would be very difficult to 
obtain intestinal fluid from volunteers. A
gastrointestinal secretion which can, however, be readily 
obtained is saliva. Evidence that salivary antibodies 
reflect intestinal responses comes from a study by 
Mestecky et a l . (93) which showed a clear antibody
response in saliva after oral vaccination with
Streptococcus. The major immunoglobulin found in saliva is 
secretory IgA (slgA). Unlike serum IgA, this is a dimer 
bound to a secretory component. One of its main functions 
is to inhibit the adherence of microorganisms to mucosal 
surfaces and thus prevent their entry into host tissue.
Two groups have looked at total slgA levels in saliva of
AS patients. Calguneri et a l . (58) found significantly
more IgA in patients with active disease than those with 
inactive disease. Pease et al . (69) demonstrated no
difference between patients and controls but no comparison 
was made between patients of different disease activities.
2.2 Aims of Study
1) To see if the reports of an association of high serum 
levels of immunoglobulins with elevated ESR and CRP in AS 
can be supported.
2) To measure spontaneous and mitogen-stimulated 
immunoglobulin production in vitro.
3) To measure IgA levels in patients' saliva.
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2.3 Subjects and Methods
Note : Unless otherwise stated, the chemicals described in 
this and all other method sections were obtained from BDH, 
UK.
2.3.1 Measurement of serum immunoglobulins
Subjects
Group A consisted of AS patients with an ESR below 30mm/hr 
and a CRP below 25jig/ml, Group B of patients with an ESR 
above 30mm/hr and a CRP above 25|ig/ml and the control 
group of normal healthy laboratory and medical staff.
In this and other studies, we have attempted to make the 
male:female ratio in the control group comparable to that 
of the patient groups since it is well recognised that sex 
can influence the immune response (as reviewed by Cohn 
(94). However, because of the large predominance of males 
with AS, the male:female ratio in the patient group is 
often higher. The details of the subject groups used in 
this study are given below.
Group A Group B Controls
Number 65 60 60
Mean age in years 
(Range)
31
(21-53)
37
(25-67)
36
(24-56)
Male:Female ratio 7.5:1 5.8:1 4.5:1
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Assay
Serum IgA, IgG and IgM levels were measured in the 
Biochemistry Department, Glasgow Royal Infirmary by an 
immunoturbidimetric assay using an ENCORE centrifugal 
analyser (Baker Instruments, UK).
2.3.2 Measurement of in vitro immunoglobulin production 
by PBLs
Subjects
Patients with active disease (A) and patients with
inactive disease (IA) as well as normal healthy 
laboratory and medical staff (C) were studied. Disease
activity was assesed using the " Point System For
Assessment Of Disease Activity " (see Appendix R  ).
Patients with a score of £ 5 were considered to have
active disease and those with a score of < 5 were
considered to have inactive disease. This system is used
in all further studies in this thesis. The details of the
groups are given below.
IA A C
Number 20 20 20
Mean age in years 
(Range)
36
(25-36)
34
(25-54)
32 
(22-41)
Male:Female ratio 6:1 5.2:1 3.9:1
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Preparation of lymphocytes
The cells were isolated under sterile conditions in a 
laminar flow hood (Microflow Pathfinder, Inter Med, USA) 
using sterile reagents. Heparinised whole blood was 
carefully layered over equal volumes of Lymphoprep 
(Nycomed, Norway) and centrifuged at 450g for 45 mins at 
room temperature. The buffy layer (mononuclear cells) was 
washed three times in Rosewell Park Memorial Institute 
(RPMI) 1640 medium (Gibco, Scotland), spinning the cells 
each time for 10 mins at 250g. The cells were counted in 
an Improved Neubauer Chamber (Hawksley, UK) using 0.05% 
trypan blue (Gibco, Scotland) in PBS and resuspended in 
RPMI containing 10% Foetal Bovine Serum (Northumbria 
Biologicals, UK) and 50IU/ml penicillin / 5|ig/ml
streptomycin (Gibco, Scotland) then adjusted to the 
required concentration.
Cell culture
500(il of the cell suspension were added in duplicate to 
the wells of sterile flat-bottom 24-well plates (Nunc, 
Denmark) . 500|il of medium, with or without PWM, were
added to each well and the plates incubated in a 
humidified atmosphere of 5% C02 in air at 37°C for the 
required number of days. The contents of each well were 
then transferred to tubes and centrifuged at 800g for 10 
mins. The supernatants were taken off and stored at -20°C 
until assayed.
ELISA.
A sandwich ELISA was used for the quantitation of 
immunoglobulin in the culture supernatants. 100|il of a 
1:100 dilution of goat anti-human IgA, IgG or IgM (Sigma, 
UK) diluted in 50mM carbonate buffer (pH9.6) were added to 
the wells of flat-bottom 96 well-plates (Sterilin, UK) and 
left to coat at 37°C for 1 hour. The wells were emptied
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by inverting the plate over a sink and tapping briskly on 
absorbent paper, then washed three times by filling with 
phosphate buffered saline containing 0.05% Tween 20 (PBS- 
Tween 20) and emptying in the same way. Non-specific 
binding sites were blocked by adding 200^1 of PBS 
containing 1% Bovine Serum Albumin (BSA) and incubating 
for 30 mins at 37°C. 100|il of the culture supernatants,
either undiluted or diluted in PBS-Tween 20, or IgA, IgG 
or IgM standards (Sigma, UK) were added in triplicate to 
the wells and incubated for 60 mins at 37°C. After three 
washes, 100|il of a 1:100 dilution of goat anti-human IgA-, 
IgG- or IgM-alkaline phosphatase conjugate (Sigma, UK) in 
PBS-Tween 20 were added and the plate incubated at 3 7 °C 
for a further 60 mins. After another three washes, 100^1 
of a 1mg/ml solution of p-nitrophenyl phosphate disodium 
(Sigma, UK) in carbonate buffer containing 1mM magnesium 
chloride were added to each well and the plates incubated 
at 37 °C until the colour developed. The reaction was 
stopped by the addition of 50|il of 3M sodium hydroxide and 
the absorbance at 405nm measured using a Titertek 
Multiskan spectrophotometer (Titertek, Finland).
2.3.3 Measurement of IgA in saliva
Subjects
Patients with active disease (A), patients with inactive 
disease (IA) and controls (C) were studied. The details 
are given over the page.
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c IA A
Number 47 28 30
Mean age in years 
(Range)
30
(21-42
38
(25-67)
37
(25-57)
Male;Female ratio 3.6: 5: 7.2 : 1
Saliva collection
Saliva was collected in the mornings only to obviate any 
effect of diurnal variation in salivary function and was 
taken at least one hour after eating. Only subjects who 
had their own teeth were studied since it is known that 
people with dentures lack many of the minor salivary 
glands. Each subject was given 2ml of a 10% solution of 
citric acid to stimulate secretion. The saliva was not 
spat out - subjects were asked to stop swallowing and 
gently "dribble" their saliva into a universal container 
until 5ml had been collected. Each sample was clarified 
by centrifuging at 2000g for 15 mins and then stored at - 
20°C until assayed.
The amount of IgA in the saliva was measured by a sandwich 
ELISA (as in section B, this chapter) using known 
concentrations of IgA as standards. Three dilutions of 
each sample - 1:400, 1:800 and 1:1600 in PBS-Tween 20
were tested and the mean result taken.
ELISA
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2.3.4 Statistical Analysis
The Mann-Whitney and Spearman-Rank tests were used (see 
Appendix B).
2^4___^esults
2.4.1 Measurement of serum immunoglobulins
Patients were divided into two groups : those with an ESR
< 30mm/hr and a CRP < 25[ig/ml (Group A) and those with an 
ESR > 30mm/hr and a CRP > 25ng/ml (Group B) . Patients who 
fell between the two groups - e.g. an ESR < 30mm/hr but a 
CRP > 25p,g/ml - were excluded.
As shown in Table 1, serum IgA and IgG levels were found 
to be considerably higher in Group B patients than Group A 
patients and controls (p < 0.001). Group A did not differ 
from the control group. There was no significant 
difference in IgM levels between any of the groups.
To determine whether there was a direct correlation 
between IgA or IgG and either ESR or CRP levels in these 
patients , a Spearman-Rank correlation test was performed. 
With ESR, r = 0.47 (p = < 0.001) for IgA and r = 0.46 (p
< 0.001) for IgG. With CRP, r = 0.46 (p < 0.001) for IgA 
and r = 0.42 (p < 0.001) for IgG. This indicates a 
moderate correlation of both values with IgA and IgG.
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Table 1 Serum immunoglobulin levels (mg/ml) in patients and controls.
Controls Patients
Group A Group B Statistical
Significance
Number 60 65 60
IgA 2.2 2.4 4.3 Controls v GpA : NS
(1.7-23) (2.0-3.1) (3.4-4.9) Controls v GpB : p =  <0.001
GpA v GpB ; p : <0.001
IgG 12.45 12.4 20.1 Controls v G p A : NS
(10.7-143) (11.4-14.0) (15.3-26.3) Controls v GpB : p = <0.001
GpAv GpB 1 p : <0.001
IgM 1.55 1.4 1.6 Controls v GpA : NS
(1.1-2.35) (1.0-2.0) (1.25-2.0) Controls v GpB : NS
GpA v GpB : NS
Group A  =  AS patients with a CRP <25 ug/ml and ESR<30 mm/h 
Group B =  AS patients with a CRP >25 ug/ml and ESR>30 mm/h 
Medians and interquartile ranges shown 
NS =  not significant
2.4.2 Measurement of in vitro immunoglobulin production 
by PBLs
ELISA standard curves
Figure II shows an example of a typical standard curve for 
each of the immunoglobulin classes studied. The most 
linear part of the curve lies within 10-800ng/ml and only 
this area was used in the assay. Any sample lying to the 
right of this area was diluted and measured again and any 
sample lying to the left was recorded as 10ng/ml.
Determining optimal conditions for cell culture
a) Cell number
1x10s , 5x10s and 1x106 mononuclear cells from five control 
subjects were stimulated with a range of PWM dilutions and 
the immunoglobulin production measured after 10 days. The 
results are shown in Figure III. Clearly, a minimal 
response is shown by 1x10s cells and an optimal response 
by 1x106 for each immunoglobulin class. However, in order 
to limit the amount of blood required for the assay, 5x10s 
cells were used since this was sufficient for significant 
immunoglobulin production.
b) PWM Dilution
5x10s mononuclear cells from five control subjects were 
stimulated with a range of PWM dilutions. The
immunoglobulin production after 10 days is shown in Figure 
IV. There is considerable variation in the optimal PWM 
dilution for different individuals : 1:50, 1:100 or 1:250
was shown to be optimal depending on the cells and the 
immunoglobulin class. It was therefore decided to use
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each of these dilutions in the assay. 
c) Incubation time
5x10s cells from five control subjects were stimulated 
with a 1:100 dilution of PWM and incubated for 5, 7, 10,
12 or 15 days. The results are shown in Figure V. Day 12 
appeared to be the appropriate day for harvesting since 
any further immunoglobulin production by day 15 was 
minimal. The slightly higher median IgM production at day 
10 (1220ng/ml compared to 1150ng/ml at day 12) was not
significant.
Comparing patient and control lymphocytes
5x105 cells from 20 patients with active disease, 20
patients with inactive disease and 20 controls were 
cultured alone or in the presence of a 1:50, 1:100 or
1:250 dilution of PWM for 12 days. Table 2 shows the
amount of immunoglobulin produced spontaneously, the 
amount produced in response to a particular PWM 
concentration (1:100) and the maximum produced at any 
concentration of mitogen. In none of the groups was a 
difference found between controls, patients with active 
disease and patients with inactive disease for any of the 
three immunoglobulin classes. When the serum
immunoglobulin levels of the subjects used in this study 
were measured, it was found that patients with active
disease had significantly higher IgA and IgG levels than 
patients with inactive disease and controls (p < 0.001 for 
both immunoglobulin classes), reflecting the trend seen in 
Table 1 .
2.4.3 Measurement of IgA in saliva
As shown in Figure VI, the salivary IgA levels in patients 
with active disease are comparable to those of patients 
with inactive disease and controls. When patients as a
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Figure VI: IgA levels in saliva of patients and 
controls as measured by ELISA
500 n
Statistical significance
C v IA = Ns 
C v A = Ns 
IA v A = Ns
400-
300-
200-
100 -
x x
X
X x
b
* x x
X
5 *  xX x 
X
Xx
X X X
X X
X
X
X
X X
X
X
x X
IA A
n = 30n = 47 n = 28
C = controls; IA = patients with inactive disease; 
A = patients with active disease 
Ns = not significant
Medians and interquartile ranges shown.
whole were compared to controls, there was also no
significant difference. It should be pointed out that the
ELISA assay used detects IgA heavy chains. It is assumed
that most of this is the secretory form of the
immunoglobulin although no attempt was made to check this 
by measuring the secretory component.
2.5 Discussion
This study confirms previous reports of high IgA and IgG
levels in the sera of patients who are thought to have
active disease on the basis of elevated levels of ESR and 
CRP (57, 59) . In addition, a moderate correlation was
found between IgA and both ESR and CRP which is similar to 
that reported by two other groups (62, 68) but is contrary
to the findings of Sanders et a l . (95) who reported a very
poor correlation with CRP (r = 0.24). The discordance
between our results and those of Sanders could be related 
in part to the different number of patients included in 
each study (120 in our study compared to only 22 in
theirs). Interestingly, IgG was found to correlate as 
well as IgA with ESR and CRP. As far as we know, we are 
the only group who has previously reported such a finding
(96) .
These high levels of immunoglobulins could reflect an 
ongoing immune response in patients with active disease. 
IgA levels are especially elevated : the median level in
patients with active disease is almost double that of 
controls. It has been suggested (57, 62) that such
findings indicate antigenic stimulation at a mucosal 
surface such as the gut since the majority of serum IgA is 
derived from plasma cells at such sites (61) . This has
lent support to the theory that an immune response to gut
bacteria is involved in the pathogenesis of AS. However, 
one might therefore expect to find high levels of IgA in 
sera from patients with gastroenteritis. Neumann et a l .
(97) found this not to be the case. The same study showed
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elevated IgA levels in Rheumatoid Arthritis (RA) and 
Psoriatic Arthritis (PsA) and the author concluded that 
these high concentrations of IgA do not indicate a gut 
infection but are a result of the inflammatory process 
associated with rheumatic diseases. Several groups (60, 
87) have found that the raised serum IgA levels in AS do 
not differ significantly from those in RA, and Collado et 
a l . (88) suggests that IgA should be regarded as an acute
phase reactant like CRP. Ebringer's is the only group to 
report that elevated serum IgA is restricted to AS and not 
found in other inflammatory diseases (52).
It does seem very likely that non-specific mechanisms are 
operating. The amount of specific antibody produced in 
response to antigenic stimulation, by a gut bacteria for 
example, is not likely to account for such a major 
elevation in immunoglobulin levels. On the other hand, a 
large number of B-cells can be non-specifically induced to 
secrete immunoglobulins by lymphokines, such as B-cell 
differentiation factor, which are produced during 
inflammation. The fact that IgA and IgG are raised while 
IgM is normal may reflect the maturity of the cells which 
are stimulated : it is known that cells which produce IgA 
and IgG are more mature than IgM-secreting cells.
Whatever the cause, it is clear that high immunoglobulin 
levels are associated with active disease as defined by 
common laboratory parameters. This supports the use of 
immunoglobulin measurements in aiding the assessment of 
disease activity, as was suggested by Franssen et a l . 
(60) . All further studies in this thesis have used the " 
Point System For Assessment Of Disease Activity " (see 
Appeddix A) which takes immunoglobulin levels into 
account.
Another of our studies looked to see if the production of 
immunoglobulins by patients' PBLs in vitro supported the 
in vivo (serum) findings. If this was the case, it might 
be possible, using co-culture experiments, to investigate
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the role of different lymphocyte populations in producing 
these high levels of immunoglobulins. Patients with
Systemic Lupus Erythematosus (SLE) have high serum levels 
of immunoglobulins and they have been shown to have 
elevated numbers of cells which spontaneously secrete 
immunoglobulins in vitro but have a reduced response to 
PWM (98). By co-culturing SLE PBLs and mitomycin-treated 
normal T-cells, one group reported that the reduced 
response to PWM was due to decreased T-cell help (98) . 
Nies et a l . (99), on the other hand, found that this low
response was not improved by co-culturing with normal T- 
cell populations and concluded that the abnormality lay 
with the B-cells themselves.
In our study, both spontaneous and PWM-induced 
immunoglobulin production by PBLs were measured as 
indicators of both the activation state of the cells in 
vivo and their capacity for further stimulation. No
abnormality in production of any of the three major 
classes of immunoglobulin could be demonstrated by the 
PBLs of AS patients. This was despite the fact that 
patients in the active disease group had elevated levels 
of serum IgA and IgG. This supports the findings of
Vuento et a l . (91) for IgA and IgG but fails to support
their demonstration of a low IgM response to PWM. They 
found that this low response was corrected by addition of 
hydrocortisone, suggesting that it was due to suppressor 
T-cells.
Clearly, our in vitro study does not reflect the findings 
in serum. There may be several explanations for this. In 
the case of IgA, it is believed that the majority of
plasma cells producing serum IgA are located at mucosal 
surfaces and studying cells from the peripheral blood may 
not therefore be the most useful approach. It is also 
possible that a high activation state of the cells is 
dependent on serum factors such as interleukins which are 
not produced in vitro. Alternatively, it could be that 
the levels of immunoglobulin produced in vitro are too low
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to reveal a difference between groups. Although
significant amounts of immunoglobulins can be measured in 
the supernatants, they are in ng/ml concentrations while 
the serum levels are measured in mg/ml. Whatever the
reason, it is clearly not possible to use co-culture 
experiments to investigate the cellular basis for the high 
levels of serum immunoglobulins found in AS patients.
IgA in patients' saliva was measured to see if it 
reflected the high levels found in serum. However, no 
significant difference was observed between controls, 
patients with active disease and patients with inactive 
disease. This is contrary to the findings of Calguneri et 
a l . (58) which demonstrate high levels of IgA in the serum
of patients with active disease. Interestingly, the 
levels found in our study are considerably higher than
those reported by Calguneri : the median level in our
active disease group was 193 jug/ml compared to a mean value 
of 55 ns/ml in theirs. The reason for this is not clear 
although different methods of collecting the saliva and a 
different assay were used : they used Curby cups (100) for 
collection and single radial immunodiffusion for their 
assay. Moreover, when comparing the groups, we used non-
parametric analysis, appropriate to the spread of the data 
while t-tests were employed in their study. This may help 
to explain the different findings of the two studies.
Our finding of normal salivary IgA in AS does not support 
the proposal of antigenic stimulation of the gut mucosal 
immune system. It may seem surprising that serum IgA is 
raised while the IgA in mucosal secretions is not since
this immunoglobulin is derived from mucosal sites. 
However, there is considerable doubt as to how well saliva 
reflects the intestinal immune response. As with their
serum studies, Neumann et al . (97, 101) demonstrated that
patients with gastroenteritis had normal levels of 
salivary IgA. Another study of acute gastroenteritis 
(102) found no evidence that bacterial - specific salivary 
antibodies correlated with antibodies in the intestinal
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fluid. Trull et al . (65), however, demonstrated elevated
salivary IgA antibodies to Salmonella in patients with 
Salmonella reactive arthritis. Clearly, an accurate 
measurement of the intestinal immune response requires 
studies of secretions and tissue from the gut itself. 
Access to these is difficult, but some such studies have 
been carried out in AS. In a preliminary study, O'Mahoney 
et a l . (103) measured IgA in the intestinal fluid and
showed that the levels in AS were normal &nd Stodell et 
a l . (104) reported that AS patients have increased numbers
of IgG-containing cells in their rectal lamina propria.
In conclusion, high serum levels of IgA and IgG are found 
in AS and are associated with active disease but the PBL 
of patients do not secrete high levels of immunoglobulins 
and patients have normal levels of IgA in their saliva.
This study has looked at non-specific immunoglobulins in 
AS. Perhaps more relevant than this is the specific 
antibody response to the environmental factors suspected 
of involvement in the pathogenesis of the disease : 
Klebsiella and other Enterobacteriaceae.
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C H A P T E R  3
A N T I - B A O T E R X A L  A N T I B O D I E S
3.1 Introduction
In Reactive Arthritis (ReA) , it has been shown that serum 
antibodies to the causative organism are elevated and can 
persist for several months. In one study, IgA antibodies 
to Yersinia were found in all 13 patients with Yersinia- 
arthritis and only 1 out of 12 patients who had an 
uncomplicated Yersinia infection. (64). These high levels 
could still be detected in the arthritic patients up to 
three years later. Trull et al . (65) found high serum
levels of Salmonella-specific antibodies (of all classes) 
in suspected cases of Salmonella-arthritis. Similarly, 
high titres of IgG and IgM antibodies to Chlamydia have 
been found in sexually-acquired ReA (63).
If, as many authors propose, AS is a form of reactive 
arthritis which is associated with Klebsiella or other 
Enterobacteriaceae (39), one would expect to find high
levels of antibody to these organisms in patients' sera.
Several groups have investigated this. In a series of 
studies which have been recently reviewed (52), Ebringer's 
group have used several techniques to demonstrate the 
presence of high levels of antibody to Klebsiella 
pneumoniae in the sera of patients with active AS. In the 
first ELISA study (105), AS patients with an ESR £ 15mm/hr 
were found to have higher levels of IgA anti-Klebsiella 
antibodies than AS patients with an ESR < 15mm/hr, patients 
with RA or Psoriatic Arthritis (PsA) and healthy controls. 
This antibody could be specifically absorbed out of the 
sera with Klebsiella and normal levels of antibody to the 
control organisms E.coli and Candida were found in these
patients. In a subsequent ELISA study in which disease 
activity was based upon CRP levels (65), patients with
active disease were found to have more IgA antibodies to
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Klebsiella than patients with inactive disease. Antibodies 
to the other Enterobacteriaceae Salmonella, Yersinia and 
Pseudomonas were similar in patients and controls, 
regardless of disease activity.
Absorption studies (39) demonstrated that the level of 
total IgA in patients' sera was significantly reduced after 
overnight incubation with Klebsiella but not Proteus or 
Streptococcus. A fourth study by the same group (106)
which used 125I -labelled Klebsiella antigen in an 
inhibition assay, was said to show higher levels of
specific antibody in the sera of patients with active
disease (although the details of this study have never been 
published) . Trull and Panayi (66) reported not only raised 
IgA antibodies to Klebsiella in the active disease group 
but a correlation between such antibodies and CRP levels.
In Scandinavian countries, the most frequent causative 
agent in ReA is Yersinia and here it is this organism 
rather than Klebsiella which is most strongly implicated in 
AS (68). High levels of Yersinia-specific antibodies have 
been detected in Scandinavian AS patients (68). In
addition, in a small study of British patients, Pease et 
a l . (69) found that serum antibodies to Yersinia but not
Klebsiella oxytoca were slightly raised in AS although this 
was not related to disease activity.
In addition to the large number of studies on bacterial- 
specific antibodies in the serum, two groups have looked at 
salivary antibodies in AS. Trull et al . (65) found that
patients had raised salivary antibodies to Klebsiella and a 
normal response to E .coli and Pseudomonas. (No comparison 
was made between patients with active and inactive 
disease.) In contrast, Pease et a l . (69) found no
elevation in the antibody response to either Klebsiella or 
Yersinia.
These studies of anti-bacterial antibodies arose out of 
reports by Ebringer's group of an increased faecal carriage 
of Klebsiella pneumoniae in AS patients with active disease
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(41, 51, 107). One study (107) showed that these bacteria
were isolated in 79% of cases of active disease compared to 
40% of cases of inactive disease and only 16% of controls. 
Another study showed that patients with a positive culture 
for Klebsiella had higher mean CRP and ESR values than 
those with negative cultures (51). A similar association 
with active disease in a native American population was 
reported by Kuberski et a l . (53). However, several groups
have failed to find an association between Klebsiella and 
the presence or activity of AS (54, 55, 56) .
3.2 Aims of Study
1) To study anti-bacterial antibodies in serum by ELISA and 
immunoblotting.
2) To measure anti-bacterial antibodies in saliva and 
lymphocyte culture supernatants.
3) To investigate the rate of carriage of Klebsiella and 
other Enterobacteriaceae.
3.3 Subjects and Methods
3.3.1 Bacterial preparations
The bacteria used were : Klebsiella pneumoniae K43,
Yersinia enterocolitica 0:3, Shigella flexneri 2a, Proteus 
mirabilis (all obtained from the National Collection of
Type Cultures, U.K.), Escherichia coli 2387 (originally 
supplied by Dr. H.Mayer, Max-Plank Institute for
Immunobiology, West Germany) and Salmonella typhimurium
SH892 (originally supplied by Dr. P.H.Makela, Central 
Public Health Laboratory, Helsinki, Finland).
The bacteria were maintained in the laboratory on Columbia 
Blood Agar or Cysteine-Lactose-Electrolyte Deficient 
(C.L.E.D.) plates (supplied by Belvidere Hospital,
29
Glasgow). Several loopfulls were innoculated into 100ml of 
Mueller-Hinton Broth (Oxoid, UK) and incubated overnight at 
370C . The bacteria were centrifuged at 1500g for 10mins, 
washed twice in PBS and counted. The concentration of each 
bacterium was calculated from its absorbance at 405nm. The 
relationship between concentration and absorbance for 
S . flexneri 2a is shown in Appendix C. For the other 
bacteria, the concentration was calculated from standard 
curves previously drawn up in our laboratory (50). Two 
bacterial preparations were made : formalin-killed and
sonicated. For formalin treatment, the bacteria were made 
up at 10s colony-forming units (CFU)/ml in PBS containing 
1% formalin and left overnight at room temperature. After 
three washes in PBS (centrifuging at 1 500g for 10 minutes), 
the cells were resuspended in PBS, recounted and stored at 
-20°C. For sonicated preparations, the cells were made up 
to 109 CFU/ml in PBS and sonicated on ice in 5ml volumes 
for 10 minutes at 10 microns. The preparation was 
centrifuged at 1500g for 10 minutes to remove intact cells. 
The protein concentration of the supernatant was measured 
using the Lowry method (205) and adjusted to 1mg/ml. This 
was stored at -20°C until used.
3.3.2 Measurement of anti-bacterial antibodies in sera, 
saliva and culture supernatants.
Subjects
a) Serum studies
30 controls (C), 29 patients with inactive disease (IA) and 
30 patients with active disease (A) were studied. The 
details of the subjects are given over the page.
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Number 30 29 30
Mean age in years 34 39 45
(range) (26-50) (24-56) (29-67)
Male:Female ratio 4:1 7.6:1 8.1:1
b) Saliva studies
The subjects were those used in section 2.3.3
c) Culture supernatants
The subjects were those used in section 2.3.2
Serum collection
10ml of venous blood were collected in glass tubes and 
allowed to clot at room temperature for two hours then 
centrifuged at 2000g for 10 mins. The serum was removed and 
stored at -70°C until tested.
ELISA
An indirect ELISA was used. 100 jrl of the bacterial 
preparation, diluted in 50mM bicarbonate buffer (pH9.6), 
were added to the wells of 96-well flat-bottom plates 
(Sterilin, UK) and left to coat at 37°C for 1 hour. The 
plates were washed and the non-specific binding sites 
blocked as previously described (Section 2.3.2). 100p,l of
the test sample, diluted in PBS-Tween 20, were added in 
triplicate to the wells and the plates were incubated at 
37°C for 60 minutes. The plates were washed three times 
and I0 0 |il of a 1:5000 dilution of biotinylated sheep anti-
human immunoglobulin (Amersham, UK) or a 1:2500 dilution of 
biotinylated goat anti-human IgA (Amersham, UK) in PBS-
Tween 20 were added and the plates left for a further 60 
minutes at 37°C. After a further three washes, 100[il of a 
1:100 dilution of a streptavidin and biotinylated alkaline 
phosphatase complex (Strep ABC Complex-Alkaline 
Phosphatase, Dakopatts, Denmark) in 50mM tris pH7.6 were
added and the plates incubated for 30 mins at 37°C. The 
substrate was added and the absorbance read as described in 
Section 2.3.2. In each test, the sample was added to wells 
which had been coated with bacteria and to uncoated (blank) 
wells. The absorbance of the blank wells was subtracted
from that of the test sample.
3.3.3 Immunoblotting of Klebsiella proteins with patients' 
sera
Subjects
From the subject groups described in Section 3.3.2, 20
control samples, 20 samples from patients with inactive 
disease and 20 samples from patients with active disease 
were studied.
Immunoblotting
Sodium duodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) was carried out using the Laemmli system (108) 
with a glass plate cassette (Gibco, Scotland) of dimensions 
15x17x0.15cm. A 10% polyacrylamide running gel was 
prepared using the following formula : 50% acrylamide mix 
(48.75% acrylamide,1.25% N,N,-methylene bisacrylamide) , 
4ml; 1M tris HCL pH8.8, 15ml; 10% SDS, 0.4ml; 1.5%
ammonium persulphate (Sigma, UK), 0.9ml; N,N,N,N-
Tetramethylethylenediamine (TEMED) (Sigma, UK), 0.025ml; 
deionised water (dHzO), 15.7ml. 32ml of this was poured 
into the cassette, overlayed with isobutanol and allowed to 
set. The isobutanol was poured off and the surface of the
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gel was rinsed with dHzO before 5ml of stacking gel was 
poured on top. The stacking gel consisted of : 50%
acrylamide mix, 1.0ml; 1M tris HCL (pH6.8), 1.25ml; 10%
SDS, 0.1ml; TEMED, 0.02ml; dHzO, 7.15ml. This was 
overlayed with isobutanol and allowed to set. After 
rinsing the stacking gel surface, the cassette was attached 
to the gel tank and both chambers were filled with 
electrode buffer (0.193M glycine, 0.025M tris base, 0.1% 
SDS) . 1 .5ml of a 500|ig/ml preparation of sonicated
Klebsiella which had been diluted in sample buffer (tris- 
HCL (pH6.8) containing 6% SDS, 6% 2-mercaptoethanol, 40%
sucrose and approximately 0.01% pyronin Y (Sigma, UK)) was 
boiled for 5 minutes and carefully layered onto the surface 
of the gel. The electrodes were connected to a power pack 
and run at a constant current of 40mA at room temperature 
for 4 hours or until the dye had reached the bottom of the 
gel.
The proteins on the gel were then electrophoretically 
transferred to nitrocellulose membranes (BIO-RAD, USA) 
using a Multiphor II Electrophoresis Unit (Pharmacia/LKB, 
UK) according to the manufacturer's instructions. The 
transfer buffer was 39mM glycine, 48mM tris base, 0.0375% 
SDS, and 20% methanol, and the electrophoresis was 
continued for 25 minutes at 200mA.
After transfer, the membrane was incubated at 4°C overnight 
in 50mM tris (pH10.3) containing 150mM sodium chloride and 
0.025% Tween-20. It was then cut into 1cm strips and each 
of these was sealed in polythene tubing (Jencons, UK) with 
5ml of the test sera, diluted in 50mM tris containing 150mM 
sodium chloride and 0.1% Tween 20 (incubation buffer). 
After 90 minutes at room temperature, the nitrocellulose 
strips were washed for 30 minutes in four changes of 
incubation buffer. They were then incubated for 60 minutes 
in a 1:500 dilution of biotinylated sheep anti-human 
immunoglobulins (Amersham, UK) or a 1:250 dilution of 
biotinylated goat anti-human IgA (Amersham, UK) in 
incubation buffer, using sufficient volume to cover the
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strips (usually 30ml). After three washes, they were 
placed in a 1:100 dilution of a streptavidin and 
biotinylated alkaline phosphatase complex (Strept ABC 
Complex-Alkaline Phosphatase, Dakopatts, Denmark) in 50mM 
tris p H 7 .6 and left for 30 minutes before washing a further 
three times. The substrate solution was prepared using the 
following formula : 0.1M ethanolamine buffer (pH9.6), 50ml; 
1g/l nitrobluetetrazolium (Sigma, UK), 5ml; 0.4% 5-bromo-4- 
chloro-3-indolyl phosphate (Sigma, UK) in 2 parts 
methanol:1 part acetone, 0.75ml; 1M magnesium chloride, 
0.2ml. The strips were incubated in the substrate solution 
and the colour allowed to develop for 20 minutes. They 
were then rinsed in HzO and left to dry. The resulting 
banding pattern was assessed by eye.
3.3.4 Isolation of Enterobacteriaceae from rectal swabs 
Subjects
Patients with inactive (IA) and active disease (A) were 
studied. The details are given below.
IA A
Number 24 27
Mean age in years 
(Range)
43
(26-29)
43
(20-77)
Male:Female ratio 7:1 4.4:1
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Method
Rectal swabs were taken by the patients themselves using 
cotton-tipped applicators ("Transwab", Medical Wire and 
Equipment, UK) . They were innoculated into several culture 
media : MacConk^y Agar (without salt), Desoxycholate
Citrate Agar (Hynes), C.L.E.D. Medium, Simmons Citrate Agar 
with 1% inositol, Columbia Blood Agar Base with 
Campylobacter skirrow and horse blood, and Selenite Broth 
Base with sodium biselenite. These were all supplied by 
Belvidere Hospital, Glasgow, and made up according to "The 
Oxoid Manual" (109). The Campylobacter plates were placed 
in an anaerobic jar (Don Whitely Scientific, UK) containing 
a hydrogen and carbon-dioxide generator envelope (BBL 
Microbiological Systems, USA) and left at 37°C for 48 
hours. The remaining cultures were incubated for 24 hours 
under aerobic conditions. A sample from each resulting 
bacterial colony was cultured onto plates containing 
Columbia Blood Agar Base with horse blood and left for 24 
hours. If necessary, further passage onto these plates was 
carried out until pure colonies were obtained. Colonies 
which were found to be Gram-negative were identified using 
an Analytical Profile Index (API) 20E (API-Bio-Merrieux, 
UK) . The Klebsiella isolates were sent to the National 
Collection of Type Cultures for identification of species 
and type.
3.3.5. Statistical Analysis
The Mann-Whitney and Chi-squared tests were used (see 
Appendix B ) .
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3.4 Results
3.4.1 Measurement of anti-bacterial antibodies in sera 
Effect of bacterial concentration
In order to determine the concentration of sonicated 
bacteria required to coat the ELISA plates, 1:100 dilutions 
of five control sera were tested against a range of 
dilutions of Klebsiella, Salmonella, Shigella, Yersinia and 
E . coli. The results are shown in Table 3. For each 
bacteria, 200|ig/ml was the concentration chosen for the 
assay since this produced high levels of antibody binding 
which were not significantly increased when 500p,g/ml were 
used.
Effect of serum concentration
Using 200p,g/ml Klebsiella to coat the wells, various 
dilutions of five control sera was tested for both total 
and IgA antibodies. The results are shown in Figure VII. 
For total antibodies (using anti-human immunoglobulins as 
the 2nd antibody) , the most linear part of the curve lies 
between a 1:100 and a 1:500 dilution of sera and for IgA 
antibodies (using anti-human IgA as the 2nd antibody), it 
lies between a 1:50 and a 1:200 dilution. Similar curves 
were obtained with the other bacteria. A 1:200 dilution 
was therefore used for the total antibody assay and a 1:100 
dilution for the IgA antibody assay.
Comparing patient and control sera
a) Total antibodies
The amount of Klebsiella-specific antibodies in the sera of 
59 patients and 30 controls was measured using the bacteria 
and serum dilutions outlined above. A patient's serum 
which was known to have significant levels of
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Enterobacteriaceae-specific antibodies was used as a 
standard. The standard was included in each plate and the 
result for each sample was expressed as : Absorbance(405nm) 
of sample / Absorbance(405nm) of standard (after 
subtracting the absorbance of the blank wells). The 
colour was allowed to develop until the absorbance of the 
standard was approximately 1.0. This practice was used in 
most of our ELISA studies of bacterial- specific antibodies.
Figure VIII shows the amount of total antibodies to
sonicated Klebsiella in controls, patients with inactive
disease and patients with active disease. There was no 
difference between any of the groups.
b) IgA antibodies
Klebsiella-specific antibodies which were exclusively of 
the IgA class were also measured (Figure IX) . The patient 
group as a whole was found to have an elevated median leval 
of specific antibody (p < 0.01) and individually both the 
active and the inactive disease group had more specific
antibodies than the controls. However, when patients with 
active disease were compared to patients with inactive
disease, no significant difference was found.
Comparing patient and control serum IgA antibodies to other 
bacteria
To see if an elevated IgA response was also found against 
other bacteria, IgA antibodies to several other members of 
the Enterobacteriaceae family were measured. Compared to 
controls, patients were found to have higher levels of IgA 
antibodies to Salmonella, Shigella and Yersinia but not to 
E . Coli or Proteus (Table 4) . Like the response to 
Klebsiella, the elevated antibody levels to Salmonella are 
not related to the activity of the disease since there is 
no significant difference between the active and the 
inactive disease group. In the case of Shigella and 
Yersinia, however, patients with active disease have more 
specific antibodies than patients with inactive disease and
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Figure VIII: Total antibodies to sonicated Klebsiella 
in the sera of patients and controls 
as measured by ELISA.
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Figure IX : IgA antibodies to sonicated Klebsiella 
in the sera of patients and controls 
as measured by ELISA.
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these patients with inactive disease have antibody levels 
comparable to that of the control group.
Absorption study
A small absorption study of three patient sera was carried 
out to determine whether the IgA antibody response to 
Klebsiella was cross-reactive with the other bacteria. 1ml 
of a 1:50 dilution of the sera was added to wells of a 24- 
well plate which had been coated with 200^g/ml sonicated 
Klebsiella. After 2 hours at 37“C, the serum was 
transferred to a second Klebsiella-coated well. This was 
repeated four times at 2 hourly intervals and the final 
incubation was at 4°C overnight. By ELISA, the levels of
antibody to various sonicated bacteria were measured in 
these serum samples (post-absorption) and compared to serum 
samples which had been incubated in the same way in 
uncoated wells (pre-absorption). For Klebsiella, it was 
found that the mean ELISA value (Absorbance (405nm) ) of the 
post-absorption samples was 40% lower than that of the pre­
absorption samples. For Salmonella, Shigella, Yersinia and 
E.coli, the levels were 23%, 20%, 19% and 19% lower,
respectively.
3.4.2 Measurement of anti-bacterial antibodies in mitogen- 
stimulated PBL culture supernatants.
Effect of concentration of formalin-killed bacteria
Table 5 shows the absorbance (405nm) of five control sera 
(1:100) tested in wells coated with a range of dilutions of 
formalin-killed bacteria. For each bacterium, 109 CFU/ml 
were found to be sufficient to produce maximum antibody 
binding and this concentration was used in all subsequent 
ELISAs of formalin-killed bacteria.
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Comparing patient and control supernatants
The mitogen-stimulated PBL culture supernatants obtained in 
Section 2.3.2 were studied for the presence of total 
antibodies to both sonicated and formalin-killed 
Klebsiella, Salmonella, Shigella and Yersinia. 1:2 
dilutions of samples from 10 patients and 10 controls were 
studied and for each individual, the culture supernatant 
which had been found to contain the maximum amount of 
immunoglobulin was used. The absorbance (405nm) readings 
obtained were all below 0.1 (The equivalent reading for the 
serum standard was approximately 1.0.) indicating that the 
culture supernatants contained negligible amounts of 
antibodies reactive with these bacteria. We nevertheless 
compared patients and controls and no differences were 
found.
3.4.3 Measurement of anti-bacterial antibodies in saliva 
Effect of saliva concentration
Figure X shows the ELISA readings obtained when various 
dilutions of control saliva (undiluted - 1:5) are tested
for antibodies to sonicated Klebsiella and Yersinia. Since 
different patterns were found, individual curves for each 
sample, not median values, are shown. Specific antibodies 
to these bacteria can be detected in the saliva but only at 
high concentrations, falling off as the sample is diluted 
to 1:5. In some cases, the antibody levels detected in the 
undiluted sample were lower than those found at a 1:2 
dilution. This is most likely due to the problem of high 
background (i.e. non-specific binding of antibody) in such 
concentrated samples. It was decided to use a dilution of 
1:3 for the assay. Although the readings obtained with 
this dilution are relatively low, we can be quite confident 
that it lies within the linear part of the curve.
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Comparing patient and control saliva
Figure XI compares the levels of IgA antibodies to 
sonicated Klebsiella and Yersinia in 20 controls, 20 
patients with inactive disease and 20 patients with active 
disease. No significant differences were found between any 
of the groups. Figure XII shows the equivalent results for 
formalin-killed bacteria and once again, no difference were 
found. There was also no significant difference when 
patients as a whole group were compared to controls.
3.4.4 Immunoblotting of Klebsiella proteins with patient 
sera
a) Total antibodies
A serum dilution of 1:200 was used as in the ELISA (Section
3.3.1). Figure XIII shows an example of an immunoblot 
obtained with a patient's serum. We found a total of 24 
distinct proteins bands (although no immunoblot contained 
all 24 bands) and the presence and intensity of each of 
these bands was noted for each serum sample. In Table 6, 
we have shown the frequency with which each band occurs in 
the control and patient groups. Clearly, some bands are 
present in the majority of the samples (e.g. bands 14-16 
which have molecular weights of around 30kD) and some are 
rarely present (e.g. band 3 which has a molecular weight of 
approximatley 92kD) . However, no band is found
significantly more frequently in any of the subject groups. 
(This was confirmed by chi-squared tests.) This suggests 
that neither the presence nor absence of antibodies to any 
of these separated proteins is associated with the presence 
or activity of AS. The intensity of the staining of each 
band was also studied (assessed by eye and scored as +-, + 
or + + ) . The strength of an antibody response to any of the 
proteins did not appear to be associated with any of the 
subject groups.
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Figure XIII. 1 mmunob lot t ing  of K lebsie l la  proteins w ith
a p a t ien t ’s serum
Approx. Mol. Wt.
 9 6kD
 66kD
 45kD
 29kD
 2 4kD
A B
A = Total antibodies; B = IgA antibodies
Table 6. Immunoblotting of Klebsiella proteins with patient and control
sera. (Total antibodies).
Protein Band Approx Mol C
Sera
IA A
No.
1
wt.
n =20
3
n=20
5
n=20
4
2 3 • 1 3
D 96kD 2 3 2
4 8 4 5
5 12 14 16
6 11 6 8
1 4 2 1
8 8 8 12
9 2 2 5
10 9 11 10
11 4 1 4
12 45kD 4 6 4
13 6 6 4
14 19 16 15
15 15 17 19
16 29kD 17 18 18
17 5 7 9
18 5 7 7
19 4 2 2
20 24kD 10 11 10
21 6 11 10
22 1 2 2
23 3 5 2
24 2 0 4
C =  controls; IA  =  patients with inactive disease; A  -  patients with 
active disease.
The protein bands were labelled consecutively in descending order of 
molecular weight.
The number of samples in each group in which the band was found is sho
b) IgA antibodies
A serum dilution of 1:100 was used as in the ELISA (Section
3.3.1). Figure XIII shows an example of an immunoblot 
obtained with a patient's serum. In the IgA immunoblots, 
only 10 of the 24 protein bands found in the total antibody 
blots could be seen and many of these bands were present at 
a much lower frequency. Table 7 shows which bands are 
found and the frequency with which they occur in each of 
the subject groups. Clearly, no band is found more 
frequently in any one of the groups. Similarly, the 
intensity of staining of any of the bands did not appear to 
differ between the groups.
3.4.5 Isolation of Enterobacteriaceae from rectal swabs
In our study of rectal swabs, Klebsiella was isolated from 
9/51 (17.6%) AS patients - 6/24 (25%) patients with
inactive disease and 3/27 (11.1%) patients with active
disease. The difference between these two groups was not 
statistically significant when compared in a chi-squared 
test. All these isolates were of the K.pneumoniae group 
and included serotypes K10, K11, K15, K21, K47, K53, K60
and K 6 1 . No K43 was identified.
Apart from E . coli which was found - not surprisingly - in 
all cases, no bacterium was isolated in large numbers. 
Both Proteus and Enterobacter were found in 5/51 (9.8%) of 
patients and their presence was not associated with active 
disease. Other Enterobacteriaceae isolated included
Citrobacter, Seratia and Hafnia but none of these was found 
in more than 5% of cases.
5^_Discussion
To investigate the possible involvement of Klebsiella in 
AS, antibodies to this bacteria were measured in patients 
sera. An ELISA test, first described by Engvall and 
Perlman (110), was used because of its high sensitivity in 
detecting antibody (111). The use of laboratory and
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Table 7 Immunoblotting of Klebsiella proteins with patient and control
sera (IgA antibodies)
Sera
Protein Band Approx Mol C IA A
No. wt.
ts II to o ’ n=19 n=20
6 66kD 0 1 0
8 0 0 2
10 3 0 2
14 17 18 16
15 11 13 13
16 29kD 10 10 12
18 2 3 3
20 24kD 2 2 1
21 0 0 1
22 0 0 1
C =  controls; IA  =  patients with inactive disease; A  =  patients with 
active disease.
The protein bands are those described in Table 6.
The number o f samples in each group in which the band was found is shown.
medical staff as controls was appropriate because of the 
reports suggesting that people who frequent health care 
facilities have increased intestinal colonisation with 
Klebsiella (54, 112).
Patients were found not to differ from controls when total 
anti-Klebsiella antibodies were studied. However, when 
antibodies of the IgA class only were measured, patients 
were shown to have significantly elevated antibody levels. 
In contrast to the findings of Ebringer et al. (52), these 
elevated anti-Klebsiella antibodies were not associated 
with active disease.
It is difficult to compare our results with those of 
Ebringer. In the four studies by Ebringer's group 
discussed (39, 67, 105, 106), three different methods of
assessing disease activity were used. In addition, the 
bacterial preparation used in their assay was different 
from ours. This is a common problem with studies of 
Klebsiella in AS: different groups use different bacterial 
preparations and serotypes, and the antigenic similarities 
and differences between these serotypes are not entirely 
clear. We used K43 since it is this serotype in particular 
which has been shown to cross-react with the B27 antigen 
and is, therefore, most strongly implicated in AS (43, 46) . 
We also chose to use both a sonicated and a formalin-killed 
preparation in most of our studies. The formalin-killed 
preparation is thought to represent surface antigens on 
intact bacteria while the sonicated sample is a collection 
of all bacterial antigens including secretory and internal 
proteins which could be exposed within a host.
Another area of conflict with Ebringer's group is our 
finding that the high IgA antibody levels are not 
restricted to Klebsiella : higher than normal levels of IgA 
antibodies to the known arthritogenic bacteria, Salmonella, 
Shigella and Yersinia were also found. In an attempt to 
determine whether the antibody response was elevated to all 
of these four bacteria simply because the response to one
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cross-reacted with the others, a limited absorption study 
was carried out. By incubating patient sera with sonicated 
Klebsiella, we reduced the antibody response to the 
autologous preparation by 40%. The response to each of the 
other bacteria was reduced by only approximately half of 
this. This suggests that the serum antibody response to 
Klebsiella consists of both antibodies specific only for 
Klebsiella and antibodies which cross-react with each of 
the other three bacteria. A considerable degree of cross- 
reactivity is known to exist between these bacteria (113). 
However, it is not possible to conclude too much from this 
absorption study since the Klebsiella was unable to absorb 
out more than 40% of the anti-Klebsiella reactivity. This 
may be partly due to the fact that the Klebsiella - since 
it was a sonicated preparation - had to be used on solid 
phase.
Further evidence that the IgA antibody responses to these 
four bacteria are different comes from our finding that the 
elevated antibody levels in AS to Shigella and Yersinia are 
associated with active disease while the high responses to 
Klebsiella and Salmonella are not.
Evidence that the high level of serum IgA antibodies to 
these bacteria are not simply a consequence of the general 
elevation in IgA seen in patients comes from the finding 
that the responses to E . coli and Proteus were normal. 
Neither of these two bacteria have been implicated in AS. 
It might be tempting to conclude that the abnormal IgA 
anti-bacterial response in AS is restricted to Klebsiella 
and arthritogenic bacteria but further studies on a range 
of organisms would be necessary before any such statement 
could be made. However, our findings do suggest that if 
Enterobacteriaceae are involved in some way in AS, there is 
probably nothing unique about Klebsiella. Although this 
organism has been the focus of a great number of studies 
over the last two decades, many now believe that a group of 
Enterobacteriaceae may be involved (114).
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Our ELISA assay and the techniques used in the other 
antibody studies discussed are limited in that they provide 
information only about the collective antibody response to 
whole bacteria or a group of bacterial antigens. One group 
has used a gel-immuno-radioassay to investigate the serum 
antibody response in AS to individual bacterial proteins 
which have been separated on polyacrylamide gels. They 
have shown (206) that while their Scandinavian AS patients 
did not have raised antibody titres to several whole 
Enterobacteriaceae, they did possess more frequently than 
controls antibodies to a 35kD heat-modifiable major outer 
membrane protein (h-momp) which is highly cross-reactive 
amongst many Enterobacteriaceae (116). This abnormal 
reactivity was confirmed by excising the protein from gels 
and testing by ELISA (117).
Another study used immunoblotting to compare the serum 
antibody response to Yersinia antigens of patients with 
Yersinia arthritis and patients with an uncopmplicated 
infection. Although no obvious difference was found in the 
blotting pattern of sera from the two groups, the IgA 
response to certain Yersinia antigens tended to persist 
longer in the arthritis patients (118).
We decided to follow this approach and used immunoblotting 
to study the serum antibody response in AS to separated 
Klebsiella proteins. In the case of IgA where high levels 
of antibodies to sonicated Klebsiella had been detected by 
ELISA, it might be possible to identify which antigens this 
elevated antibody response is directed towards. It could 
be that only patient sera recognise a particular antigen or 
that they make a higher than normal response to it. In the 
case of antibodies of other immunoglobulin classes, the 
overall response to the bacteria could be normal (as we 
found in our total antibody ELISA) while an abnormal 
antibody response to individual antigens is revealed by 
immunoblotting.
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Our results revealed, no obvious difference between the 
immunoblots of controls, patients with inactive disease and 
patients with active disease, suggesting that neither the 
presence nor the activity of the disease is associated with 
a particular antibody response to any of the separated 
proteins. However, there were several problems with the 
interpretation of these blots. Firstly, the presence and 
the intensity of the staining of the bands could not be 
quantitatively determined but was assessed by eye, causing 
much subjectivity. Different levels of background staining 
made scoring difficult and in some cases, there was poor 
resolution between bands. It is probably safe to say, 
however, that any gross abnormality would have been 
revealed.
Clearly, the blots do not reflect the ELISA results. The 
serum samples from patients with active disease used in 
this study had demonstrated an elevated median level of IgA 
antibodies to Klebsiella in the ELISA (Section 3.4.1). 
When the IgA blots of the 10 patient sera which had given 
ELISA values above 0.4 (see Figure VIII) were compared to 
those of control sera (all control sera values below 0.4), 
there was no obvious difference. There could be several 
explanations for this. The elevated antibody response may 
be directed towards non-protein antigens such as capsular 
polysaccharides, to protein antigens not present on the 
blot (e.g. because they are too large to get into the gel) 
or to protein antigens in their native state only - before 
dissociation by 2 -mercaptoethanol and denaturation by SDS.
This immunoblotting study was also limited because of its 
use of such a complex antigenic preparation. Sonicated 
Klebsiella is made up of a very large number of proteins 
and some of the bands may represent several proteins of 
similar molecular weight. It would perhaps be more useful 
to immunoblot a selection of proteins, particularly those 
thought to be most immunogenically relevant such as 
membrane proteins. We attempted to isolate outer membrane 
proteins from Klebsiella by treatment with sarkosyl (119)
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but were unable to obtain reproducible preparations for
immunoblotting.
In conclusion, this immunoblotting study has not provided 
us with any more information on the immune response to 
Klebsiella in AS patients.
Anti-bacterial antibodies were also measured in the 
supernatants of PWM-stimulated PBL cultures to determine 
whether patient lymphocyte populations contain a high 
number of bacterial- specific clones. Although significant 
levels of immunoglobulins had been detected in these 
supernatants (e.g. ng/ml quantities of IgM), negligible 
amounts of antibodies to Klebsiella, Salmonella, Shigella 
and Yersinia were found in both patients and controls by an 
ELISA. A similar finding was reported by Cavender et al. 
(92). However, it is perhaps unreasonable to expect to 
find detectable levels of such antibodies in these 
supernatants. Using our ELISA, antibodies to these 
bacteria are hardly detectable in patients' sera at 
dilutions higher than 1:1000 and such serum samples contain 
more total immunoglobulin than we detected in the 
supernatants (see Section 2.4.2).
A more useful study of the in vitro humoral immune response 
to Enterobacteriaceae in AS might involve stimulating theI
cells specifically so that only bacterial - specif ic clones 
would be expanded, as in the Jerne plaque assay (120).
IgA antibodies to Klebsiella and Yersinia were measured in 
saliva and most subjects were found to have detectable 
amounts of such antibodies (although these were 
considerably lower than serum levels). Neither patients as 
a whole nor the active disease group had higher than normal 
levels. This supports the findings on Klebsiella of Pease 
at a l . (69) and contrasts with those of Trull et.al. (66).
The use of different bacterial preparations might explain 
these different findings. Like Pease's group, we studied 
sonicated Klebsiella (as well as a formalin-killed 
preparation) while Trull's group used Klebsiella culture
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supernatants as their antigen. It is perhaps possible that 
the patients' salivary antibody response is elevated only 
to certain secreted bacterial proteins and that this is not 
apparent when a complex mixture of antigens - such as a 
sonicated preparation - is used.
We encountered, however, a number of problems in our ELISA 
measurements of salivary antibodies. One problem was high 
non-specific binding of some samples. For example, the 
test sample (i.e. in wells coated with bacteria) could have 
an absorbance reading of 0.6 while the background sample 
(i.e. in uncoated wells) was as high as 0.4. It is not 
clear how meaningful an absorbance value for specific 
binding of 0.2 would be in such a case. This high non­
specific binding is due in part to the high saliva 
concentration required for the assay. Moreover, although 
the saliva dilution used in the assay lay within a linear 
part of the ELISA curve, in some cases this did not have a 
steep gradient (see Figure X ) .
Finally, although we have looked at antibodies in the 
saliva in the hope that they may be more relevant than the 
serum antibody response to intestinal pathogens, there is 
some controversy over how well salivary antibodies reflect 
the humoral response in the gut (as discussed in Chapter 
2 ) .
With these problems in mind, our findings of normal 
salivary antibodies to Klebsiella and Yersinia in AS are in 
contrast to our serum studies and do not lend support to 
the proposal of an involvement of these gut bacteria in the 
disease.
As well as the many studies on antibodies to Klebsiella in 
AS, there has been much interest in the faecal carriage of 
this organism. Much controversy exists over whether 
patients with active disease differ from those with 
inactive disease or controls in their rate of faecal 
carriage of Klebsiella, and this study sought to determine 
the isolation rate in the patients who attend our out­
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patient clinic. Most studies have been concerned 
exclusively with Klebsiella, using culture conditions 
selective for the growth of this organism. However, 
because of the possibility that other bacteria may be 
involved in AS, we looked to see if any other 
Enterobacteriaceae were found at a significant level in 
patients. A range of different culture media were used in 
the hope of isolating as many of the bacteria of interest 
as possible.
The results obtained provide no evidence for a high rate of 
faecal carriage of Klebsiella in AS and this supports 
previous findings in our laboratory (121). We isolated 
this organism from patients at a frequency (17.6%) lower 
than that reported by many other groups (51, 107) and found 
no difference between patients with active and inactive 
disease. It is notable that none of the isolated
Klebsiella were K43, the serotype which has been most 
implicated in AS. In addition, no other member of the 
family Enterobacteriaceae was isolated at a rate high 
enough to suspect it of any association with the disease or 
to warrant further investigation (e.g. by looking at 
healthy controls) . In no case were any of the known
arthritogenic bacteria found.
It could be argued that the low recovery rate of organisms 
is due to the use of rectal swabs. It is certainly 
possible that rectal swabs do not provide as good an 
indicator of bowel flora as faecal samples. In the 
majority of studies in AS, faecal samples have been used 
although a few (53, 55) have used rectal swabs. Our choice
of rectal swabs was a purely practical one : it was simpler
for the patients and they were therefore much more likely 
to co-operate.
The only finding in this series of studies which suggests 
any association between Enterobacteriaceae and AS is that 
of high levels of antibody to sonicated bacteria in 
patients' sera. This finding does not necessarily imply
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that the bacteria play any pathogenic role in the disease. 
One study (122) has demonstrated high levels of complement- 
fixing antibodies to Yersinia and Campylobacter in several 
seronegative spondyloarthropathies and the author suggests 
that this could be a consequence of the tendency of 
rheumatic patients to be prone to some infections. 
Recently, Cooper et a l . (50, 123) found raised serum IgA
antibodies to Klebsiella and Yersinia in RA, Ulcerative 
Colitis and Crohn's Disease as well as AS, and the author 
concluded that increased permeability of the gut to 
bacterial antigens may be responsible for the elevated 
immune response. There is some evidence that AS patients 
do have abnormal bowel permeability (124) and that this is 
related to the use of NSAIDs (125, 126). These findings
conflict with those of Ebringer's group who have 
demonstrated a normal anti-Klebsiella response in other 
rheumatic diseases such as RA and PsA (52) .
The findings of raised serum anti-bacterial antibodies in 
AS cannot be interpreted until we have established whether 
this is restricted to AS and exactly which group of 
organisms are involved.
This study has measured antibodies in the serum and saliva 
but AS is a disease of the joints. Our next approach was 
therefore to look for any evidence of a local immune 
response to Enterobacteriaceae in these joints.
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CHAPTER 4
ANTI - BACTERIAL RESPONSES IN
THE JOINT
4.1 Introduction
Chronic arthritis can be induced in rats by the injection 
of streptococcal cell walls but the disease does not 
develop in athyraic rats unless they are given infusions of 
T-lymphocytes (127). This indicates that the cellular 
immune response of the host can play an important role in 
arthritis.
Both specific and non-specific cell-mediated immune
responses of peripheral blood lymphocytes have been 
studied quite extensively in AS. There are conflicting 
reports on the in vitro proliferation of such cells after 
non-specific stimulation with mitogens. In general, when 
measured by uptake of tritiated (3H) thymidine, the 
response to PWM and Concavalin A are normal (77, 79) but 
some groups have demonstrated decreased lymphocyte
proliferation in response to Phytohaemagglutinin (PHA) 
(24, 77) while others (78, 1 9, 128) have reported normal
responses to this mitogen.
Because of the proposal of a bacterial involvement in AS, 
several groups have looked for an abnormality in the 
specific response of patients' blood lymphocytes to 
bacterial antigens with equally conflicting results. The 
earliest report was by Nikbin et al. (78) who found a
significantly reduced proliferative response to Yersinia
in AS patients. This was associated with the B27 antigen
rather than the disease itself. Another group (24, 43)
demonstrated a reduced response to several isolates of 
Klebsiella which was independent of B27. However, there 
have been several reports of normal proliferation in 
response to Klebsiella (79, 80) and Yersinia (80, 129).
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Unlike many of the investigators who failed to take into 
account factors which can influence cell-mediated immunity 
such as age, sex and drug treatment, Kinsella et al. (79) 
used age- and sex-matched patient-control pairs and 
withdrew patients from medication prior to the study. In 
addition, only Klebsiella which had been directly isolated 
from AS patients were used as antigen in this study, and 
in some cases the cells were stimulated with autogenous 
faecal isolates. No difference was found in the 
proliferative response of patients and controls.
When another indicator of lymphocyte function was studied, 
an increased response to Klebsiella was found in AS. 
Gross et a l . (130, 131) showed that while T-cell
proliferation in response to various preparations of 
Klebsiella was generally poor in both patients and 
controls, the bacteria induced a significantly higher 
production of Leucocyte Migration Inhibitory Factor (LIF) 
in patients' cells. LIF is a lymphokine, produced mainly 
by T-cells, which plays an important part in cell-mediated 
immunity : it inhibits the migration of macrophages,
causing them to accumulate at the site of inflammation. 
This heightened LIF response in AS was said to correlate 
with disease activity.
In a study of ReA, the same group (131) showed that the 
LIF response of PBLs to Yersinia was higher in patients 
with Yersinia-arthritis than in patients with 
uncomplicated yersiniosis. In addition, proliferation 
studies by Brenner et a l . (129) revealed a marked increase
in the response to Yersinia in Reiter's Syndrome. This 
was found only with the arthritogenic strain Yersinia 
enterocolitica 0:3 and not with Yersinia enterocolitica 
0:8, a serotype which has not been implicated in 
arthritis. However, one group found a normal response to 
a range of Enterobacteriaceae in RS (80) and another group 
has reported a significantly lower proliferative response 
to Yersinia in Yersinia-arthritis (132).
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Clearly, much controversy exists over the cell-mediated 
responses to bacteria in both AS and ReA. However, these 
studies have been concerned with the immu)ne response of 
lymphocytes from the peripheral blood. What about the 
site of inflammation - the joint? In ReA, there is 
increasing evidence that bacterial antigens are present in 
the joints and that synovial lymphocytes respond much more 
vigorously to these antigens than blood lymphocytes do.
Attempts to culture viable organisms from joints have 
failed (35, 36) but recent immunohistochemical studies
using rabbit antisera and monoclonal antibodies have 
indicated the presence of chlamydial elementary bodies in 
the synovial tissue of patients with sexually-acquired ReA 
(36) and RS (133). In Yersinia-arthritis, one group has 
demonstrated bacterial components in synovial cells by 
both immunofluorescence and immunoblotting (134) and also 
found these antigens within immune complexes derived from 
synovial fluid (135). In these studies, the bacterial 
antigens were associated with polymorphonuclear or 
mononuclear phagocytes. Similar findings have been
reported in chronic arthritis in rats which has been
induced by injection of streptococcal cell walls (127).
Several investigators have found evidence for a local 
cell-mediated immune response in the joints of ReA
patients to the organism which precipitated the disease. 
In several cases of enteric ReA, synovial lymphocytes have 
been shown to proliferate most vigorously in response to 
the causative organism, make a marked response to other, 
cross - reactive Enterobacteriaceae and to make little or no 
response to the sexually-transmitted organisms Chlamydia 
and Ureaplasma (136, 137). Cells from patients with
sexually-acquired ReA responded to Chlamydia and
Ureaplasma but not to Enterobacteriaceae. In RA (138) and 
arthritis associated with inflammatory bowel disease 
(139), synovial cells did not respond significantly to any 
of these organisms. The authors concluded that the
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synovial lymphocyte response could be used to diagnose the 
cause of the precipitating infection in ReA.
Gaston et a l . (140) have reported very similar results.
By inhibiting with Cyclosporin A and monoclonal 
antibodies, they have shown that the synovial response in 
ReA is mediated by class II restricted T-cells. They also 
demonstrated marked proliferation in the presence of a 
65kD heat shock protein in several cases of enteric ReA, 
suggesting that the synovial cell response is directed, in 
part, to this highly cross-reactive bacterial antigen 
(141). In addition, Hermann et al. (142) were recently 
able to generate a number of Yersinia-specif ic T-cell 
clones from the synovial fluid of patients with Yersinia- 
arthritis .
In these studies, marked synovial lymphocyte responses 
were often present in the absence of a significant 
response by PBLs. For example, the stimulation index (cpm 
of stimulated cultures / cpm of unstimulated cultures) of 
synovial cells could be > 200 while that of PBL was < 3 
for the same organism (143). This suggests that the
bacterial- specific synovial lymphocytes are not derived 
from the circulation but are either selectively recruited 
to the joint or, more likely, clonally expanded within the 
joint itself.
Despite these studies on cell-mediated immunity in ReA, as
far as it is known, only one group has looked at the
humoral response in the joints. Keat et al. (63) measured 
antibodies to Chlamydia in the synovial fluid from 
patients with sexually-acquired arthritis. They found 
titres of specific antibody similar to that found in the 
sera, providing no evidence for local antibody 
production.
So far, very little attempt has been made to study the
local immune response - either cell-mediated or humoral 
in AS. Ford et a l . (137) showed that synovial lymphocytes
frpm a small group of six AS patients were unable to make
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a significant proliferative response to Klebsiella, 
far we know, no other such studies have been carried out
4.2 Aims of Study
1) To study the proliferative response of synovial 
lymphocytes to Klebsiella.
2) To study anti-bacterial antibodies in the synovial 
fluid by ELISA and immunoblotting.
4.3 Subjects and Methods
4.3.1 Collection of synovial fluids and isolation of 
synovial lymphocytes
All the synovial fluids were aspirated from knee joints. 
Each fluid was collected in universals containing 200^1 of 
20% ethylenediaminetetraacetic acid (EDTA) and centrifuged 
at 250g for 15 minutes. The supernatant was taken off, 
centrifuged again at 2000g for 10 minutes to remove any 
remaining cells then aliquoted and stored at -70°C until 
required. Under sterile conditions in a laminar flow hood 
("Microflow Pathfinder", Inter Med, USA), the cell pellet 
from the 250g spin was resuspended in RPMI 1640 medium and 
layered over equal volumes of Lymphoprep. The mononuclear 
cells were separated, washed and counted as described in 
Section 2.3.2. They were then resuspended in RPMI 1640 
medium containing 10% dimethylsulphoxide (Sigma, UK) and 
20% pooled human serum at a concentration of 5X106-107 
cells/ml. The cell suspension was transferred to
polypropylene cryogenic vials (Bibby, UK) and immediately 
stored at -70°C. The following day, the vials were 
transferred into liquid nitrogen and maintained in this 
(at -196°C) until required.
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4.3.2 Measurement of synovial lymphocyte proliferative
responses to Klebsiella
Subjects
Synovial lymphocytes were collected from the following 
patients.
AS Others
Number 6* 11
Mean aqe in years 33 47
(range) (13-63) (22-57)
Male:Female ratio All male 0.8:1
* Synovial fluid was collected twice from two of the 
patients (6 months and 14 months apart) giving a total of 
8 AS samples.
The " Others " group was made up of 7 RA and 4 Psoriatic 
arthrtis patients.
.Bacterial preparations
Formalin-killed Klebsiella was prepared as in section
3.3.1 except that after incubation in formalin, the 
bacteria were kept under sterile conditions. Sterile PBS 
was used for resuspension and all manipulations were 
carried out in a laminar flow hood. A sonicated 
preparation was made up as in section 3.3.1 except that 
the final preparation was sterile- filtered using 0.45[im 
disposable filters (Gelman Sciences, USA) .
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Cellculture
The cryopreserved mononuclear cells (Section were
thawed at 37 °C and immediately added to lOanl fpwtt m -,1 q am a 
centrifuged at 2 50g for 1,0 minutes. They were washed 
twice in the medium, recounted and made up to the required 
concentration in medium containing 10% pooled huiiaiin serum 
and 50IU penicillin / 5p,g/ml streptomycin (complete 
culture medium). 100^1 of the cell suspension were added 
in triplicate to the wells of 96-well round bottom plates 
(Corning, UK). 100^1 of one of the Klebsiella
preparations, made up in complete culture medium, were 
added to the wells. The plates were incubated in a
humidified atmosphere of 5% C02 in air at 37°C for the 
required number of days. A solution of tritiated 
thymidine was made up as follows : (methyl 3H) thymidine
at 1mCi/ml (Amersham, UK), 0.5ml ; 5^M "cold" thymidine,
0.1ml ; complete culture medium, 9.4ml. 20|il of this were
added to each well and the plates were incubated for a 
further 18 hours. The cells were harvested onto filter 
mats (Skatron, UK) using an automated cell harvester 
(Skatron, UK) . After drying overnight, the paper discs 
were transferred to scintillation vials (Packard, UK) and 
the vials filled with 4ml toluene (May and Baker, UK) 
containing 4g/l of 2,5-diphenyloxazole (Packard, UK). The 
radioactivity in the vials was measured using a beta 
scintillation counter (Rackbeta II Liquid Scintillation 
Counter, LKB, U K ) . The uptake of tritiated thymidine by 
the cells gave a measure of their proliferation. The 
results were expressed as counts per minute (cpm) or as 
the stimulation index. The stimulation index was :
cpm of stimulated cells / cpm of unstimulated cells.
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4.3.3 Measurement of anti-bacterial antibodies in
synovial fluids
Subjects
Synovial fluids from the following patients were studied
AS RA Others
Number 13 15 12
Mean age in years 39 53 41
(range) (13-70) (41-72) (38-47)
Male;Female ratio 12:1 0.5:1 1.2:1
The patients in the " Others " group were made up of : 3 
PsA, 3 Adult Stills Disease, 2 Osteoarthritis, 2 SLE, 2 
Gout and one of unknown origin.
ELISA
The ELISA was carried out as for serum antibodies as 
described in Section 3.3.2. 109 CFU/ml of formalin-killed
or 200|ig/ml of sonicated bacteria were used to coat the 
ELISA plates.
4.3.4 Immunoblotting of Klebsiella proteins with synovial 
fluids
Subj ects
12 AS, 10 RA and 10 "Other" samples were taken from the 
subjects described in the previous section.
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Immunoblotting
Immunoblotting (total antibodies) was carried out as for 
serum antibodies as described in Section 3.3.3.
4.3.5 Statistical Analysis
The Mann-Whitney test was used (see Appendix B) .
4.4 Results
4.4.1 Measurement of synovial lymphocyte proliferative 
responses to Klebsiella
Effect of cell number and bacterial concentration
10s, 5x10s and 106 synovial cells from three non-AS
patients were stimulated with a range of concentrations of 
formalin-killed and sonicated Klebsiella. Table 8 shows 
the results from one patient. There was a wide scatter in 
the values obtained with the different patients but the 
same trend was found in all three. The maximum response 
was obtained when 106 cells were stimulated with 107 
CFU/ml of formalin-killed or 20|ig/ml of sonicated 
bacteria. These antigen concentrations were therefore 
used in our assay. Cell numbers higher than 106 were not 
tested since we had insufficient numbers of most of the 
frozen cells to use more than this in the assay.
Effect of incubation time
Figure XIV shows the results obtained when 10® synovial 
cells from three non-AS patients were incubated with 107 
CFU/ml of formalin-killed or 20\ig/ml of sonicated 
Klebsiella for a period of 3,4,5 or 6 days. In two out of 
three cases, a 4 -day incubation was optimal for both 
antigen preparations. The third sample gave maximum 
proliferation at day 5 but this was only slightly higher 
than the proliferation obtained at day 4. A 4 -day 
incubation period was therefore used in the assay.
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Table 8 Effect of cell number and bacterial concentration on the proliferative 
response of synovial lymphocytes to Klebsiella (as measured by 
uptake of 3H-Thymidine).
(a) Formalin-killed bacteria.
Cone, of bacteria (CFU/ml)
no. synovial cells 10* 5 x  10* 107 5 x 107 10*
105 2.1* 2.1 2.4 0.8 1.4
(154) (155) (183) (62) (109)
5 x 105 6.5 8.3 10.6 6.4 1.5
(931) (1191) (1517) (926) (209)
10* 7.1 8.7 12.7** 8.6 1.6
(1477) (1798) (2616) (1792) (327)
(b) Sonicated bacteria. C o n e . of bacteria (Mg/m 1)
no. synovial cells 1 5 10 20 50 100
105 1.3 1.4 1.7 1.9 1.9 1.0
(526) (567) (688) (770) (769) (405)
5 x 105 1.9 2.3 2.2 3.8 1.8 0.9
(1430) (1732) (1657) (2861) (1356) (678)
10* 2.7 5.4 5.1 8J** 6.3 2.1
(4555) (9109) (8603) (14339) (10628) (3542
^Results expressed as: Stimulation index
(cpm)
Stimulation index = cpm of stimulated cells
cpm of unstimulated cells
CFU = colony forming units 
** Maximum values.
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Effect of PHA concentration
106 cells from three non-AS patients were stimulated with 
a range of concentrations of PHA in a 4 -day incubation. 
The results are shown in Table 9. 25ng/ml PHA induced a 
maximum response in all three cases and this was used for 
the assay.
Comparing lymphocytes from AS and other patients
Using the optimal conditions outlined in the previous 
sections, we measured the proliferative response to 
Klebsiella of synovial lymphocytes from 8 AS and 11 other 
patients. The stimulation indices are shown in Figure XV. 
The data are quite widely scattered and the responses are 
generally low. No significant difference was found 
between the two groups for either formalin-killed or 
sonicated bacteria.
PHA responses
To determine whether the synovial cells studied were 
capable of a high proliferative response, they were 
stimulated non-specifically with PHA. The median
stimulation index for the AS patients was 38 and for the 
control patients was 28. These values are not much lower 
than those reported (144) for PBL from healthy donors. 
Synovial cells which had a low stimulation index in 
response to Klebsiella often had a high PHA response. 
This suggests that a low response to Klebsiella indicates 
a lack of antigen-specific clones rather than a poor 
ability of the cells to proliferate (for example, because 
of damage caused by the freezing of the cells).
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Table 9. Effect o f PH A  concentration on non-specific stimulation o f  
synovial lymphocytes.
*
Cone, o f PHA (ug/ml)
Synovial
lymphocytes
2.5 5 25 50 125
(a) 18.8
(2385)
29.8
(3783)
28.9
(3668)
21.3
(2702)
13.8
(1760)
CO 16.5
(9162)
44.5
(24705)
50.0
(27185)
42.6
(23639)
16.6
(9248)
(c) 38.6
(17351)
246
(11835)
333
(149671)
213
(95637)
69.2
(31070)
* results expressed as : Stimulation index
(cpm)
Stimulation index =  cpm of stimulated cells
cpm of unstimulated cells
Synovial lymphocytes from 3 non-AS patients were studied.
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Comparing lymphocytes from synovial fluid and peripheral 
blood
We had, unfortunately, matched PBLs for only three of the 
AS synovial samples. The stimulation indices of these 
three matched pairs are shown below.
Stimulation Index
Formalin-killed Klebsiella Sonicated Klebsiella
Synovial cells PBL
7.3 5.1
3.0 6.3
2.8 2.1
Synovial cells PBL
27.5 16.4
14.6 32.5
6.7 4.2
Clearly, no pattern emerges when these three synovial and 
blood samples are compared.
4.4.2 Measurements of anti-bacterial antibodies in
synovial fluids
Effect of synovial fluid concentration
A range of dilutions of four synovial fluids were tested 
against sonicated and formalin-killed bacteria. The 
results for Klebsiella are shown in Figures XVI and XVII. 
Similar dilution curves were obtained with the other 
bacteria Salmonella, Shigella and Yersinia. Dilutions of 
synovial fluid which lay within the most linear part of 
the curve were chosen for the assay. In the case of 
sonicated bacteria, a 1:100 dilution was used in the total 
antibody ELISA and a 1:80 dilution for the IgA antibody 
ELISA. A 1:40 dilution was used for testing both total 
and IgA antibodies to formalin-killed bacteria.
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Comparing synovial fluids from AS and other patients
Using the dilutions outlined above, both total and IgA 
antibodies to Klebsiella, Salmonella, Shigella and 
Yersinia were measured in the synovial fluid from 13 AS 
patients, 15 RA patients and 12 patients with a variety of 
other diseases including PsA, SLE, Osteoarthritis and 
Gout. The AS patient group did not have higher levels of 
antibody to any of the bacteria than either of the other 
two patient groups (Table 10 and Table 11). In addition, 
when tested in one experiment, the absorbance values of 
the AS samples in response to these four bacteria were not 
significantly different from those found in response to
E . coli.
4.4.3 Immunoblotting of Klebsiella proteins with synovial 
fluids
Synovial fluids were studied for the presence of total
antibodies to separated Klebsiella proteins by 
immunoblotting. A 1:100 dilution of the fluids was used 
as in the ELISA (Section 4.4.2). The resulting
immunoblots were similar to those found with patient sera 
(Section 3.3.4). Table 12 shows the frequency with which 
each protein band occurs in the AS, RA and " Others "
patient groups. Clearly, no band can be said to be 
associated - by its presence or absence - with the AS
patient group.
5 Discussion
In AS, no consistent abnormality has been demonstrated in 
the cell-mediated immunity to Enterobacteriaceae. However, 
all but one (137) of the reported studies have looked at 
lymphocytes from the peripheral blood. In ReA, marked 
proliferative responses to the causative organism have 
been demonstrated in lymphocytes from the synovial joints
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Table 12 Immunoblotting of Klebsiella proteins with synovial fluids from AS
and other patients.
Protein band Approx mol. AS R A Other;
No. w t n=12 n=10 n = 1 0
1 1 1 0
2 0 0 0
3 96kD 1 1 1
4 1 2 2
5 7 5 4
6 66kD 6 5 3
7 3 4 1
8 3 4 3
9 2 2 4
10 4 7 3
11 3 3 2
12 45kD 1 2 2
13 -\ 5 7 6
14
\
12 7 9
15 11 10 9
16 29kD 9 8 5
17 4 3 2
18 2 3 0
19 3 1 2
20 24kD 5 7 3
21 4 4 4
22 1 2 1
23 2 0 2
24 3 2 0
* Included patients with Psoriatic arthritis, Systemic Lupus Erythematosus, 
Osteoarthritis and Adult Still’s Disease.
The protein bands were labelled consecutively in descending order o f  
molecular weight.
The number o f samples in each group in which the band was found is 
shown.
in the absence of a significant response by PBLs (137).
We therefore decided to look for evidence for a local
cell-mediated immune response to Klebsiella within the
joints of AS patients.
The proliferative response to Klebsiella of AS synovial 
lymphocytes was found to be comparable with that of 
synovial cells from patients with other arthritic diseases 
in which Klebsiella has not been implicated. The 
stimulation indices for both sonicated and formalin-killed 
bacterial preparations were generally low. They were 
considerably lower than those reported (143) for
lymphocytes from ReA patients in response to the infecting 
organism ( >200 in some cases). In addition, we found no 
evidence that the responses of synovial cells were higher 
than those of PBLs in a study of three synovial-blood
lymphocyte matched pairs. This may be too small a number 
with which to draw any real conclusions but the median
stimulation indices of our eight synovial samples were
within the range of those reported by others (24, 79, 80) 
for patients' PBLs. Taken together, these results suggest 
that there is no significant cellular response to
Klebsiella within the joints of AS patients.
The results of this and other studies of cellular immunity 
must, however, be interpreted with caution. It is known 
that age and sex can influence cell-mediated immunity (94) 
but apart from Kinsella et a l . (79), none of the studies
discussed made an attempt to match subject groups for 
these variables. Owing to the limited availability of 
synovial samples, we were unable to control for these 
factors in our study but there were not large differences 
between our two patient groups.
Non-steroidal anti-inflammatory drugs (NSAIDs) can have an 
inhibitory effect on cell-mediated responses (145) and the 
majority of AS patients receive such drugs as part of 
their treatment. This could account, in part, for the 
absence of a significant anti-Klebsiella response.
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Although most of the patients in the control group will 
also have been receiving NSAID treatment, patients are 
given a variety of drugs and doses and these could 
influence the immune response to varying degrees.
After we had isolated the synovial cells, they were stored 
in liquid nitrogen until we had collected a sufficient 
number of samples to study. This meant that cells were 
frozen for various lengths of time, some stored for up to 
18 months. Although we used a recommended
cryopreservation technique which is routinely used in our 
laboratory and is thought to preserve cell function (146), 
it is possible that storage of cells in this way affects 
their functional activity. However, the responses 
observed to PHA suggest that the cells had retained a high 
proliferative capacity.
The effect of these various factors on cellular immunity 
may be particularly important in our study because of the 
small number of samples that we collected (8 AS and 11 
others). AS patients do not often require joint effusions 
and the yield of synovial cells from those that do is not 
always sufficient for this type of assay. Moreover, , the 
data in each of our groups are quite widely scattered : 
the cellular responses of individuals vary quite 
considerably. It is possible that a difference between 
the two groups would emerge if a larger number of samples 
were studied. However, our study gives no indication that 
lymphocytes from the joints of AS patients make the strong 
response to Klebsiella that ReA synovial lymphocytes make 
to the infecting organism.
It is possible that the cellular response to bacteria as a 
whole is normal while an abnormal response to individual 
bacterial antigens occurs. An attempt is underway in our 
laboratory to study the cellular immune response to 
individual bacterial proteins such as heat-shock proteins 
in AS and other arthritic diseases.
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In addition to the study of cellular immunity, we 
investigated the humoral response to Enterobacteriaceae in 
the joints. By ELISA, total and IgA antibodies to 
Klebsiella and the three arthritogenic bacteria 
Salmonella, Shigella and Yersinia were measured in 
synovial fluids from AS patients, RA patients and patients 
with a variety of diseases including PsA, SLE and Gout. 
No significant difference was observed between the three 
groups for any of the bacteria. In addition, the levels 
of antibody in AS synovial fluids to each of these four 
bacteria was no higher than that to E . coli, a Gram- 
negative organism which has not been implicated in the 
disease. We also studied anti-Klebsiella antibodies in 
the synovial fluid by immunoblotting and were unable to 
detect a difference between the groups with respect to the 
presence of antibodies to any of the protein bands. (The 
limitations of the immunoblotting procedure are discussed 
in Section 3.5.) These results suggest that there is no 
significant humoral immune response to these 
Enterobacteriaceae within the joints in AS.
The cell-mediated immune response of synovial cells in AS 
was studied because of the known high responsiveness of 
ReA synovial cells to the infecting organism but there is 
very little data on the humoral response in the ReA joint. 
Keat et a l . (163) found that the synovial fluid from
patients with sexually-acquired ReA contained antibodies 
to Chlamydia but these were found in levels comparable to 
that of the serum, suggesting that they were circulating 
antibodies, derived from the peripheral blood rather than 
locally produced. This lack of humoral immunity may seem 
surprising in view of the marked cellular responses 
reported in ReA. However, different types of antigen can 
selectively elicit a particular type of immune response 
(e.g. cell-mediated immunity is preferentially induced by 
cell associated antigens such as viral particles). 
Further studies on humoral immunity in ReA joints are 
necessary and would help us to interpret our findings in 
AS. In our out-patient clinic, cases of ReA with a known
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bacterial origin are not very common and we were unable to 
collect a sufficient number of synovial fluids from such 
patients to carry out any useful study.
Currently, studies by other investigators in our 
laboratory are involved in looking for the presence of 
bacterial antigens within the synovial joints. Using an 
ELISA to measure the reactivity of rabbit anti-Klebsiella 
antisera to synovial fluids, no evidence was found for the 
presence of Klebsiella antigens in the synovial fluids of 
AS patients (147). Immunohistochemical studies using 
synovial tissue and cells derived from synovial fluid are 
currently underway. The presence of bacterial antigens 
within the joint is not, however, necessary for a 
bacterial- specific immune response to occur there. 
According to the molecular mimicry theory, antigenic 
stimulation by Klebsiella could take place in the gut, and 
specifically activated lymphocytes could circulate to the 
joint where they are stimulated by the cross-reactive B27 
antigen.
It should be borne in mind that these and other studies of 
the joints in AS use material from peripheral joints since 
this is all that is normally available. However, 
peripheral arhthritis develops in only about 20% of AS 
patients (148) and it is characterised by a non-specific 
synovitis which is histologically different from the 
classical enthesis of AS. It is therefore possible that 
the pathogenic mechanisms involved in the peripheral 
disease are distinct from those of the spinal disease.
In conclusion, this study provided no evidence for an 
immune response to Enterobacteriaceae in the peripheral 
joints of AS patients.
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5.1 Introduction
In a humoral immune response, specific antibodies are 
elicited which bind non-covalently to the antigen forming 
immune complexes. These complexes have an important 
physiological role : by aggregating antigen and
interacting with phagocytic cells via Fc and complement 
receptors, they help in the clearance of antigen from the 
host. They can, however, be harmful : when deposited in 
tissue, they can activate complement leading to local 
inflammation and tissue damage. In this way, immune 
complexes are thought to play an important role in the 
pathogenesis of several diseases such as 
glomerulonephritis, SLE (149) and RA (150). In some 
cases, the levels of circulating immune complexes (CIC) in 
the sera have been shown to correlate with the activity of 
the disease (151).
In a search for evidence for the role of the immune system 
in AS, several groups have measured CIC levels in AS 
patients. A number of assays have been used and many 
conflicting results have been reported. Several studies 
have detected CIC in the sera of over 50% of patients 
using a variety of methods : a Raji cell radioimmunoassay 
(70, 71), a conglutinin binding assay (71), a C1q binding
assay (70), a polyethylene glycol (PEG) precipitation and 
single radial immunodiffusion (SRID) assay (72), PEG 
precipitation laser nephelometry (73), measurement of 
macromolecular C3 (74) and inhibition of antibody mediated 
cytotoxicity (75) . In each of these studies, a sample was 
considered positive for CIC when the levels were above the 
normal range (usually mean + 2SD of control samples). In 
contrast, there have been several reports of a low 
frequency of CIC in AS (in some cases, less than 10%).
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The assays used in these studies include a C1q binding
assay (152, 153, 154), an anti-C3 assay (71) and a
fluorescent antibody immunophagocytosis assay (155).
Clearly, there is a lack of agreement between the results 
of different groups and different assays. CIC were 
demonstrated by Espinoza et a l . (70) in 83% of AS patients
using a C1q binding assay but Rosenburg et a l . (152) were
unable to detect CIC in any of their patients with the 
same type of assay. In the study by Rosenbaum et a l .
(71), 71% of AS patients were found to have CIC levels
above the normal range in the Raji assay while only 14% of
the same samples proved positive in an anti-C3 assay.
Perhaps surprisingly, only a few of the studies mentioned 
have looked at the association between CIC and disease 
activity. Deicher et a l . (73), Panayi et a l . (74) and
Espinoza et a l . (70) found that high levels of CIC were
associated with active disease while no such association 
was found by Corrigal et a l . (75) . In two of these
studies, conclusions were based upon data from a small
number of patients (thirteen (74) and eighteen (75)).
It is notable that Deicher et a l . (73) who demonstrated an
association between CIC and disease activity, used ESR as 
their only measure of activity. ESR has been shown to 
correlate better with the peripheral arthritis of AS than 
with the spondylitis (84) . Moreover, in the study of
Espinoza et a l . (70), the presence of peripheral joint
involvement was one of the criteria used in assessing a 
patient as having active disease, and the highest levels 
of CIC were seen during periods of peripheral synovitis. 
In their review, McGuigan et a l . (156), suggest that high
levels of CIC in AS may not be related to the spondylitis 
at all but to the peripheral arthritis. It is certainly 
possible that distinct pathogenetic mechanisms are 
involved at these two sites. Unlike the spinal disease, 
the peripheral synovitis of AS is histologically similar 
to that of RA (157, 158), a disease in which CIC are known
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to play an , important pathogenetic role (150). However, 
little attempt has been made to study directly the 
association between CIC and peripheral joint disease in 
AS. Panayi et a l . (74) and Corrigal et a l . (75) have
compared patients with and without peripheral joint 
involvement and found no difference between the two groups 
but once again, small numbers of patients were studied.
As well as the possibility that they play a role in the 
disease, CIC could be useful in the identification of any 
environmental factor associated with AS : where there is 
an immune complex, there is usually an antigen and it may 
be possible to isolate the complex and identify the 
antigen. In some immune complex-mediated diseases caused 
by infectious organisms such as infective endocarditis 
(159) and Hepatitis B virus - induced vasculitis (160), 
components of the infecting organism have been 
demonstrated within the CIC by techniques such as 
immunoblotting. The presence of bacterial antigens within 
CIC have been demonstrated in the reactive arthritides. 
Lahesmaa-Rantala et a l . (161) used an ELISA to show the
presence of Yersinia-specif ic IgM- and IgA- CIC in the 
sera of patients with Yersinia-arthritis (at levels higher 
than those of patients with uncomplicated yersiniosis). 
The same assay was used to demonstrate Yersinia-specific 
CIC in synovial fluids (135).
Some attempt has been made to look for disease-specif ic 
antigens within CIC in AS. Using PEG precipitation and 
acid dissociation of complexes, Bruneau et a l . (76) found
that components of CIC from AS patients bound to each 
other but not to precipitates from RA and SLE patients, 
suggesting the presence of disease-specific antigens. 
Rodahl et a l . (162) have used immunoblotting to
demonstrate a 70kD envelope glycoprotein of a psoriasis- 
associated retrovirus-like particle in the CIC from some 
AS patients. By an ELISA of alkaline-dissociated
complexes, they demonstrated antibodies to another 
psoriasis-associated protein (27kD) in CIC from sera and
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synovial fluids (163). As far as it is known, there have 
been no reported studies on the presence of Klebsiella 
within CIC in AS.
5 ^ 2 A i m s o f S ^ d Y
1) To measure CIC in AS and investigate their association 
with disease activity and the presence of peripheral 
arthritis.
2) To look for the presence of Klebsiella antigens within 
CIC by immunoblotting.
5.3 Subjects and Methods
5.3.1 Measurement of CIC levels in sera using the Raji 
assay
Subjects
Patients with active disease (A), patients with inactive 
disease (IA) and controls (C) were studied. The details 
are given over the page.
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c IA A
Number 39 29 30
Mean age in years 
(Range)
31
(22-50)
45
(26-68)
36
(24-62)
Male:Female ratio 3 :1 7:1 5.2:1
Collection of samples
Sera and synovial fluids were collected as previously 
described (Sections 3.3.2 and 4.3.1). Samples were not 
thawed more than once.
Maintenance of Raji cells
Cells from the lymphoblastoid Raji cell line (Flow, UK) 
were grown under sterile conditions in RPMI 1640 medium 
containing 10% heat-inactivated FCS and 50IU penicillin / 
5|ig/ml streptomycin. The cells were placed in 75cm2 
tissue culture flasks (Bibby, UK) at a density of 2x10s 
cells/ml and incubated in a humidified atmosphere of 5% 
C02 in air at 37 °C. Every 3-4 days, the cells were 
counted in 0.05% trypan blue using an Improved Neubauer 
Chamber and readjusted to a density of 2x105/ml in fresh 
medium. Cells which had been passaged three days 
previously were used in the assay.
Iodination of anti-human IgG
The method described by Barkas et a l . (164) was used.
1mCi (10|il) of carrier-free (125I) sodium iodide 
(Amersham, UK) was added to 1ml of a 1 mg/ml solution of 
purified goat anti-human IgG (Sigma, UK) followed by 100(xl 
of a 0.2mg/ml dilution of Chloramine T (Sigma, UK). The 
mixture was gently shaken at room temperature for 5
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minutes. 100^1 of a 0.2mg/ml solution of sodium
metabisulphite (Sigma, UK) was then added and the mixture 
carefully pipetted on to the top of a 20 x 1cm glass 
column (Bio-Rad, USA) which had been packed with Sephadex 
G25 (Pharmacia, Sweden) and equilibrated with 30ml of PBS 
containing 1% BSA. The column was eluted with PBS 
containing 1% BSA and 5 minute fractions (approximately 
0.5ml) were collected. 5(il aliquots were counted on a 
gamma counter (Packard, U.K.). The first peak of 
radioactivity represented the labelled antibody and the 
fractions making up this peak were pooled, made up to a 
volume of 3ml and stored in 1ml aliquots at -20°C.
Preparation of aggregated human IgG (AHG) standards.
A 1mg/ml solution of purified human IgG (Sigma, UK) in 
saline was heated in a water bath at 63 °C for 30 minutes 
to aggregate the protein. The AHG was then stored in 
200|j,l volumes at -70°C. (The aliquots were thawed once 
only and stored no longer than one month.) On the day of 
the assay, nine doubling dilutions of AHG in saline were 
prepared from a starting concentration of 500(j.g/ml. To 
each of these, 50(il of a 1:2 dilution of pooled normal 
human serum (NHS) were added (as a source of complement) 
and the samples incubated for 30 minutes at 37°C. These 
were used as the standards.
Assay
The method described by Theofilopolous (165) was used. 
The test sera were spun at 1000g for 10 minutes to remove 
large aggregates then diluted 1:2 in saline. 25|il volumes 
were added in duplicate to 2x106 Raji cells which had been 
washed and resuspended in 50[il of RPMI 1640 medium. The 
samples were incubated for 45 minutes at 37°C with gentle 
shaking every 10 minutes. 1ml of the medium was added to 
each sample and the cells spun at 800g for 10 minutes at 
4 0C . The cell pellets were washed twice more in the same 
way then incubated with 25|il of the optimum dilution of 
125I-labelled goat anti-human IgG in RPMI 1 640 containing
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1% human serum albumin (RPMI-HSA). After a 30 minute 
incubation at 4°C, the cells were washed three times in 
RPMI-HSA and the radioactivity of the cell pellet was 
measured in a gamma counter. The amount of CIC present in 
the test sera was determined using a standard curve 
obtained by incubating the cells with 25|U of the AHG 
standards. The results were expressed as jig/ml AHG 
equivalents.
5.3.2_____Measurement of CIC levels in sera using
polyethylene glycol precipitation and single radial 
immunodiffusion (PEG-SRID)
Subjects
The subjects described in the previous section were used. 
Assay
A commercially available kit (" Merrid CIC Kit ", Mercia 
Diagnostics, UK) was used according to the manufacturer's 
instructions. Briefly, 100|xl of a 12% solution of PEG was 
added to 500[il of sera and the mixture left for 3 hours at 
4°C. Complexed material was precipitated by centrifuging 
at 1500g for 20 minutes at 4°C and washed twice in washing 
buffer. The pellet was resuspended in 500|il of buffered 
saline and incubated at 37°C for 30 minutes. 10(il of each 
sample were dispensed into the wells of SRID plates 
containing anti-human IgG or anti-human IgM. The plates 
were left at room temperature for 48 hours then stained 
with coomassie blue stain. The diameter of the
precipitation rings around the wells was measured. The 
concentration of immunoglobulin was determined from the 
ring diameter using the conversion table provided.
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5.3.3 Immunoblotting of immune complexes with anti-
Klebsiella antisera
Subjects
a) Sera
6 patient and 6 control samples from the subjects 
described in Section 5.3.1 were studied. The 6 samples in 
each group which contained the highest levels of CIC were 
used.
b) Synovial fluids
6 AS and 5 other patients (2 RA, 2 PsA and 1 SLE) were
studied.
Anti-Klebsiella antisera
Two rabbit antisera specific for Klebsiella pneumoniae K43 
were used. One was prepared by another investigator in
our laboratory : New Zealand white rabbits were injected 
with formalin-killed Klebsiella on five occasions over a 
period of ten weeks. The other was kindly provided by Dr. 
Tyrone Pitt (Central Public Health Laboratory, Colindale). 
The reactivity of the antisera to Klebsiella was tested in 
an ELISA as described in Section 3.3.2 except that a 
1:1000 dilution of biotinylated anti-rabbit immunoglobulin 
(Amersham, UK) was used as the second antibody.
PEG precipitation and immunoblotting of immune complexes
10ml of sera or 10-30ml of synovial fluid were mixed with 
a final dilution of 2% PEG 6000 in PBS and left for 3 
hours at 4°C. Complexed material was precipitated by 
centrifuging at 1500g for 20 minutes at 4°C then washed
twice in 2% PEG. The pellet was resuspended in 200^1 of
PBS and the protein concentration determined using a Lowry 
assay. It was then mixed with gel sample buffer (Section 
3.3.3) to give a final dilution of 2mg/ml. 20[il of each 
sample were run on a 10% SDS-polyacrylamide gel and
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electrophoretically transferred to nitrocellulose 
membranes as described in Section 3.3.3. Immunoblotting 
was carried out as previously described (Section 3.3.3) 
except that a 1:1000 dilution of rabbit anti- Klebsiella 
antisera was used as the first antibody and a 1:500 
dilution of biotinylated anti-rabbit immunoglobulin 
(Amersham, UK) as the second.
5.3.4 Statistical Analysis
Mann-Whitney, Spearman-rank and Chi-squared tests were 
used (see Appendix B.)
5^ 4Results
5.4.1 Measurement of CIC levels in sera using the Raji 
assay
Effect of concentration of iodinated anti-human IgG
To determine the optimum dilution of 125I-anti-human IgG, 
various dilutions of the antibody were added to 2x106 Raji 
cells which had been incubated with a 1:2 dilution of NHS 
containing 500|ig/ml of AHG or with a 1:2 dilution of NHS 
alone. The resulting uptake of i25i is shown in Figure 
XVIII. The optimum antibody dilution is the dilution 
which produces the highest difference between cells 
incubated with and without AHG. At a 1:4 dilution, the 
difference is equivalent to 290 x 103 cpm and this is only 
slightly increased (302 x 103 cpm) when a 1:2 dilution is 
used. This experiment was repeated and a similar result 
was obtained. A 1:4 dilution of the antibody was
therefore used in the assay.
Standard curves
An example of a standard curve is shown in Figure XIX.
The linear part of the curve lies within the range 4-
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250|ig/ml AHG. Any sample lying to the right of this was 
diluted and re-tested and any sample lying to the left was 
recorded as 4ng/ml.
Comparing patient and control sera
CIC levels were measured in the sera of 30 patients with 
active disease, 29 patients with inactive disease and 39 
controls. The levels found in the total patient group 
(median = 44 (ig/ml AHG equivalents; interquartile range = 
4-87 [ig/ml AHG equivalents) were significantly higher (p < 
0.05) than those of the control group (median = 20 p,g/ml 
AHG equivalents; interquartile range = 4-46 jig/ml AHG
equivalents). A much greater difference was found when 
the CIC levels of patients with active disease were 
compared to those of controls (p < 0.001) or patients with 
inactive disease (p < 0.001) as shown in Figure XX.
In order to compare our results with those of others, the 
results were also expressed as the number of patients who 
were " positive " for CIC - i.e. those with CIC levels 
above the normal range. The 95th percentile was taken as 
the upper limit of normal values. 36% (21/59) of all
patients were found to be positive for CIC : 63% (19/30)
of patients with active disease and 7% (2/29) of patients 
with inactive disease. The difference between these two 
groups was highly significant (chi2 = 18.1; p < 0.001).
Comparing sera from patients with and without peripheral 
joint disease
The possibility of an association between CIC and 
peripheral joint disease was studied. The presence of 
peripheral joint disease was one of the factors considered 
in our assessment of AS activity and all patients with 
peripheral joint disease studied were in the active 
disease group. We therefore compared only patients with 
(n = 14) and patients without (n = 16) peripheral
involvement within this active group. The CIC levels are 
shown in Figure XXI.
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There was no significant difference between the two groups 
when the median levels were compared. In addition, 62% 
(10/16) of patients with and 57% (8/14) of patients
without peripheral joint disease had CIC levels above the 
normal range and the difference between the two groups was 
not significant in a chi-squared test.
5.4.2 Measurement of CIC levels in sera and synovial 
fluids using the PEG-SRID assay
a) Sera
Comparing patients and controls
The serum samples which had been tested in the Raji assay 
were also studied for the levels of IgG- and IgM- CIC 
using a PEG-SRID assay. The lower limit of detection of 
the assay was 6|ig/ml. IgG-CIC were detected in 10% (4/39) 
of control samples and 41% (24/59) of patient samples and 
the difference between the two groups was significant in 
a chi2 test (chi2 = 9.2; p < 0.01). When the median
levels of CIC were compared in a Mann-Whitney test, a 
significant difference was also found (p < 0.01) (See
Figure XXII) . The high CIC levels in patients were not
dependent on disease activity since the number of positive
samples in the active disease group (14/30) was not 
significantly different from that of the inactive disease 
group (10/29) and the median levels in the two groups were 
the same.
In the case of IgM-CIC, there was no difference between 
the patient and control groups or the the active and
inactive disease groups when either the number of samples 
with detectable CIC or the median levels were compared.
Comparing patients with and without peripheral joint 
disease
Patients in the active disease group who had peripheral 
joint disease were compared to those who had no peripheral
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involvement. The results are shown in Figure XXIII. No 
significant differences were found.
b) Synovial fluids
IgG-CIC and IgM-CIC were measured in the synovial fluids 
of 7 AS and 15 RA patients. IgG-CIC were detected in 6/7 
AS patients and the median level was 94|ig/ml 
(interquartile range = 12-257jig/ml) . This was not
significantly different from the levels found in RA 
patients (median = 20|ig/ml; interquartile range = 6-
71 |ig/ml) . IgM-CIC were detected in 3/7 AS patients and 
the median level (8|ig/ml; interquartile range = 2-32^g/ml) 
was not significantly different from that of RA patients.
5.4.3 Correlation between the Raji and PEG-SRID assays
The correlation between the results of the Raji assay and 
the PEG-SRID assay was studied using a Spearman-rank test. 
A co-efficient of 0.43 (p < 0.05) was obtained indicating 
that there was a statistically significant but low 
correlation between the two assays.
5.4. 4 Immunoblottinq of immune complexes with anti-
Klebsiella antisera
Reactivity of antisera to Klebsiella
The reactivity of the two antisera to formalin-killed 
Klebsiella (K43) was studied by an ELISA. 1:1000 
dilutions gave absorbance (405nm) readings of 0.86 and 
0.78, suggesting that the sera contained high levels of 
anti-Klebsiella antibodies. The equivalent absorbance 
reading for the pre-immune serum was 0.02. When used in 
immunoblotting of sonicated Klebsiella, the antisera 
dilution showed dense staining of a large number of bands.
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Immunoblotting of immune complexes
An attempt was made to look for the presence of Klebsiella 
antigens within immune complexes from AS patients. PEG 
precipitates of sera from 6 AS and 6 control subjects were 
separated on SDS-polyacrylamide gels and immunoblotted 
with an anti-Klebsiella rabbit antiserum or the 
corresponding pre-immune serum. Figure XXIV shows the 
very similar blotting pattern obtained with the two sera. 
The dense band of around 50kD was also found in the 
absence of either rabbit sera : this is the heavy chain of 
IgG which is recognised by the biotinylated anti-rabbit 
immunoglobulin. In addition to this, there are six bands 
which are obtained with the pre-immune serum as well as 
with the anti-Klebsiella serum. This reactivity can 
therefore be explained by the previous antigenic exposure 
of the rabbit. Two bands with molecular weights of around 
70-80kD were found in some of the samples with the immune 
serum only, suggesting that this response is "due to anti- 
Klebsiella antibodies. However, these bands were found in 
the controls as well as the AS samples. This suggests 
that they are simply commonly found "Klebsiella-like" 
antigens. No bands of molecular weights above 80kD were 
seen in any of the samples. The same PEG precipitates 
were immunoblotted with another anti-Klebsiella antiserum. 
A different banding pattern was obtained, but again, there 
was no difference between AS and control samples. (There 
was no corresponding pre-immune sample available for this 
antiserum.)
We also studied immune complexes from synovial fluids. 
PEG precipitates from the synovial fluid of 6 AS and 5 
control patients (2 RA, 2 PsA and 1 SLE) were 
immunoblotted with an anti-Klebsiella antiserum. A
different blotting pattern from that obtained with the 
serum samples was found. Again, there were bands which 
were found with both the immune and the pre-immune sera. 
Three bands with molecular weights of around 30-40kD 
appeared only or more strongly with the immune serum, but
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this occurred in the controls as well as the AS samples. 
One band (around 80kD) was present only in the AS group 
but it was found in only one of the six samples. (The 
photograph taken of these blots was unclear and is not 
shown.)
Instead of transferring the proteins for immunoblotting, 
some gels were stained and up to 15 distinct bands could 
be seen. There were no bands found in the AS group which 
were absent from the control group.
5.5 Discussion
This study sought to determine whether AS patients have 
high levels of circulating immune complexes as has been 
previously reported (70, 71 , 73) and to see whether these
CIC are associated with active disease or peripheral joint 
involvement. Two methods were used - a radioimmunoassay 
based on the ability of immune complexes to bind to a 
human lymphoblastoid cell line (Raji) via complement 
receptors, and a PEG-SRID assay which is based on the 
ability of 2% PEG to selectively insolubilise complexed 
immunoglobulin. The Raji assay was designed to measure 
IgG-CIC and the PEG-SRID assay could detect CIC containing 
different immunoglobulin isotypes.
The results of the Raji assay suggest that, compared to 
controls, AS patients have high levels of IgG-CIC and this 
is associated with active disease. Measurement of the 
same samples in the PEG-SRID assay also revealed a 
significant difference between IgG-CIC levels in the sera 
of patients and controls but this was independent of 
disease activity.
In the PEG-SRID assay, we compared absolute levels of 
complexed immunoglobulin (|ig/ml) but some authors (151) 
express their results as a percentage of the total 
concentration of the immunoglobulin in the serum. It is
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possible that a sample has a high level of complexed 
immunoglobulin because the level of total immunoglobulin 
is high. We were unable to express our results in this 
way because of the large number of samples in which 
undectable levels of CIC were found but evidence that the 
CIC levels measured in this assay were not dependent on 
serum immunoglobulin levels comes from the finding that 
while high levels of serum immunoglobulins are associated 
with active disease (see Section 1.4.1), high 
concentrations of CIC were not.
IgM-CIC were not found at a higher frequency in AS 
patients than controls and there was no difference between 
patients with active and inactive disease. This finding 
of high concentrations of IgG-CIC but not IgM-CIC is as 
one might expect in a chronic disease : IgM is an antibody 
class normally associated with a primary immune response.
We also attempted to measure CIC containing IgA : none
were detected in any of the samples. However, we suspect 
that this is due to an inability of the technique to 
detect such complexes rather than their absence in AS. 
Serum samples from ten patients with IgA nephropathy - a 
disease associated with IgA-CIC (166) - also gave negative 
results. It could be that IgA-complexes have properties 
which make them unsuitable for detection in this type of
assay - e.g. they may be less soluble because of their
inability to fix complement and may not diffuse well in 
agar. It seems unlikely that IgG- and IgM- but not IgA- 
CIC are present in AS since it is IgA immunoglobulins and 
antibodies which are most commonly raised in AS (see 
Chapters 2 and 3) . Moreover, the presence of IgA within 
CIC of AS patients has been demonstrated by other 
investigators (72, 155). In any further studies, another
assay for measuring IgA-CIC should be used - e.g. PEG
precipitation coupled with an ELISA.
Our results differ somewhat from those of other studies in 
which the same assays have been used. Using the Raji
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assay, we found higher than normal levels of CIC in 36% of 
patients when taken as a whole while Espinoza et a l . (70)
and Rosenbaum et a l . (71) reported high levels in 73% and
69% of patients respectively. This cannot be explained by 
a lower percentage of patients with active disease in our 
study since we had the highest percentage (51%) of such 
patients. It is probably because of the relatively
high levels of CIC found in our control population. In 
both of the studies described, the upper limit of the 
normal range was below 25(ig/ml AHG equivalents while we 
found this to be 74|j,g/ml. (It should be pointed out that 
most studies of CIC use mean + 2SD of the control samples 
as the upper limit of the normal range; we used the 95th 
percentile which is more appropriate to the non-normal 
distribution of the data.) The reason for these
relatively high control CIC levels is not clear although 
sample selection may play a significant part. It is known 
that many factors such as diet and exercise can influence 
CIC levels (167). Moreover, although subjects who had a 
known or recent infection were excluded from our study, we 
cannot rule out the possibility of sub-clinical 
infections.
There was not a good correlation between the results of 
the two assays used in our study. The high IgG-CIC levels 
found in AS by the Raji assay were strongly associated 
with active disease while PEG-SRID revealed a high 
concentration which was independant of disease activity. 
In addition, a low correlation co-efficient was obtained 
in a correlation test.
A lack of correlation between CIC assays is quite commonly 
found. Immune complexes are a very heterogenous
population. They can differ from each other in several 
ways including size, antigen composition, antibody class, 
antigen : antibody ratio and solubility. Over thirty
methods have been developed for the detection of CIC 
(168). Each assay is based on one of several properties 
of immune complexes - e.g. their size, their ability to
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bind to complement components, their ablilty to interact 
with Fc or complement receptors on cells or with 
rheumatoid factors. Assays based on different principles 
can often give very different results. In an inter­
laboratory study (169) in which seven methods were 
compared, only two pairs of tests were found to correlate 
significantly with each other and the highest correlation 
co-efficient was under 0.5. A WHO collaborative study of 
eighteen methods demonstrated that some techniques are 
more suitable than others for detecting CIC in certain 
diseases (170).
In view of this, the WHO report recommended that two or 
more assays based on different principles should be used 
in any study of CIC. We chose the Raji assay since this 
was reported to be one of the most sensitive and reliable 
methods by a joint IUIS/WHO working group (168). The PEG- 
SRID assay was used because of its ability to detect CIC 
of different immunoglobulin classes.
Neither of the two assays can detect all CIC. The Raji 
assay only detects complement-fixing antibodies and not 
all IgG antibodies can fix complement (although most do) . 
The PEG-SRID assay measures both complement-fixing and 
non-complement-fixing antibodies but some low molecular 
complexes may not be insolubilised in 2% PEG (151). It 
seems, therefore, that IgG-CIC which are measurable by the 
PEG-SRID assay are elevated in AS patients regardless of 
disease activity while those measured in the Raji assay 
are only found at high levels in patients with active 
disease.
The results of neither assay on serum immune complexes 
provided evidence that CIC are involved in peripheral 
joint disease : patients with and without peripheral
arthritis had similar levels of serum IgG-CIC in both 
assays and similar IgM-CIC levels were found by PEG-SRID. 
However, if immune complexes are involved in peripheral 
disease, one might expect to find them concentrated in the
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joints themselves. By PEG-SRID, we measured the levels of 
IgG and IgM immune complexes in AS synovial fluids and 
found them to be comparable to that of synovial fluids 
from patients with RA, a disease associated with high 
levels of immune complexes in the joints. Moreover, 
although we were unable to study matched synovial fluid - 
serum pairs, the median level of IgG complexes in sera 
from patients with peripheral joint disease was only 
6[ig/ml (the lower limit of detection of the assay) while 
that of the synovial fluids studied was 92^g/ml.
These high levels of immune complexes could be due to the 
predominance of some disease related-antigen within the 
joint. However, immune complexes may simply be deposited 
in the joints from the circulation because of the 
increased vascular permeability of inflamed tissue. 
Moreover, the inflamed joint is a site of tissue damage 
and many of the antigens within synovial fluid immune 
complexes may be components of damaged tissue.
Their presence in the circulation or within the joints 
does not necessarily mean that immune complexes play any 
pathogenic role in AS, and there is no evidence that they 
do. The usual manifestations of immune-complex-mediated 
diseases such as vasculitis and glomerulonephritis are not 
found in AS (171) except for a few reported cases of IgA 
nephropathy (172, 173). Not all immune complexes induce
inflammation and it has been reported that CIC in AS 
contain high concentrations of C3 and C4, making them more 
soluble and therefore less likely to cause tissue damage 
(73) .
Although they may not be pathogenic, the presence of 
immune complexes suggests that there is an ongoing immune 
response in AS. By studying these immune complexes, we 
may find evidence for the involvement of some 
environmental factor, such as Klebsiella, in the disease. 
Using immunoblotting, we looked for the presence of 
Klebsiella antigens within immune complexes (PEG
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precipitates) from sera and synovial fluids. Anti-
Klebsiella antisera had similar reactivity to PEG 
precipitates from AS and control samples, providing no 
evidence for the presence of Klebsiella in AS immune 
complexes.
This was, however, only a preliminary study using a very 
crude preparation of immune complexes. Although PEG can 
separate complexed immunoglobulins from free 
immunoglobulins, it will also insolubilise other large 
proteins. In the immunoblots obtained with the serum 
precipitates, many of the bands found may represent normal 
serum proteins and the different blotting pattern seen 
with the synovial fluid samples may be largely due to the 
different protein composition of synovial fluid.
Removal of irrelevant proteins and concentration of immune 
complexes may be necessary. Several methods have been 
used for the purification of immune complexes in various 
diseases : e.g. PEG precipitation followed by sucrose
density ultracentrifugation (174), gel filtration and 
affinity chromatography with Protein A (175), and affinity 
chromatography on conglutinin columns (176). We attempted 
to isolate immune complexes from PEG precipitates using 
gel filtration but were unable to obtain a sharp peak of 
immunoglobulin in the high molecular weight fractions (as 
measured by ELISA).
As discussed in Chapter 3, one of the problems with the 
immunoblotting technique used is the possibility that the 
proteins lose their antigenicity after denaturation. An 
ELISA might be useful in looking for intact Klebsiella 
antigens within immune complexes. Moreover, complexes can 
be dissociated by alterations in pH and the antigen and 
antibody fractions can be studied separately for the 
presence of Klebsiella antigens or Klebsiella-specific 
antibodies.
It should, however, be borne in mind that CIC do not 
necessarily contain exogenous antigen. For example,
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immune complexes can be formed through immunoglobulin- 
anti - immunoglobulin interactions : by definition,
seronegative spondyloarthropathies are not assocoated with 
rheumatoid factor, but some immune complexes may be made 
up of idiotype-anti-idiotype antibodies. As already 
discussed, damaged tissue and dietary antigens can be 
components of immune complexes. Moreover, it is possible 
that any complexes of interest are not found free in the 
circulation or the synovial fluid, but are deposited in 
tissue such as the synovium.
In conclusion, AS patients have high levels of circulating 
immune complexes and an understanding of the aetiology of 
the disease may come from identification of the antigenic 
components of these complexes. We found no evidence for 
the presence of Klebsiella, antigens but a more extensive 
search for this and other suspected agents is required.
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C H A P T E R  6
C R O S S -R E A C T X V X T Y  S T U D I E S
6 ^ 1 I n t r o d u c t i o n
Molecular mimicry or cross-reactivity occurs when two 
different proteins have similar antigenic determinants 
such that an immune response raised against one protein 
also reacts with the other. Cross-reactivity between 
microbial antigens and host tissue is thought to play a 
role in several autoimmune diseases in man : an immune
response to the infecting organism is elicited, breaking 
normal tolerance to the cross-reactive host tissue. The 
best known example is Rheumatic Fever which is preceeded 
by an infection with Streptococcus pyogenes 
Streptococcal cell walls cross-react with human heart 
tissue (26) and patients with the disease have high levels 
of heart-reactive antibodies which can be absorbed out by 
the bacteria (177). Similarly, Coxsackie B virus is 
thought to produce myocarditis in humans and experimental 
animals by cross-reacting with heart tissue (178), and
cross - reaction between agliadin and an adenovirus may play 
a role in coeliac disease (179).
Since the discovery of the strong B27 association in AS 
(13, 14) and the reports that patients have both high
faecal carriage of Klebsiella (41, 53, 107) and high
levels of antibody to this bacterium (67, 105), the
possibility of cross-rection between B27 and Klebsiella 
has been extensively studied.
Ebringer1s group (180) investigated this by studying the 
reactivity of anti-Klebsiella antisera to B27-positive 
(B27+) and B27-negative (B27-) lymphocytes using an ELISA. 
They found that B27+ cells, either from AS patients or
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healthy controls, were more reactive with anti-Klebsiella 
antisera than were B27- cells. Similar results were 
obtained when a complement-dependent microcytotoxicity
assay was used (40) . In a reverse experiment, antisera 
were raised in rabbits against B27+ cells and their
ability to bind to various bacterial preparations was 
studied by immunodiffusion, agglutination and radiobinding 
experiments (25, 40). These anti-B27 antisera showed
significantly higher reactivity to certain strains of 
Klebsiella, Yersinia and Enterobacter than sera from 
unimmunised rabbits. Similar studies were carried out 
using tissue-typing sera which are obtained from pregnant 
women immunised with foetal lymphocytes carrying paternal 
HLA antigens. By haemagglutination, radiobinding and
competitive radioimmunoassays, anti-B27 tissue-typing sera 
were shown to be more reactive to Klebsiella than were 
antisera specific for other HLA-B locus products or HLA-A- 
specific sera (42).
While Ebringer's group propose that cross-reaction occurs 
between Klebsiella and the B27 molecule itself, Geczy and 
his co-workers (46) maintain that anti-KLebsiella antisera 
show reactivity to the cells of B27+ AS patients because a 
Klebsiella-derived component is found on the surface of 
these cells in close association with the B27 antigen. 
Using a chromium-release assay, they showed that antisera 
raised against certain strains of Klebsiella specifically 
lysed approximately 80% of lymphocytes from B27+ patients 
(B27+ AS+) but none of the lymphocytes from B27- patients 
(B27- AS+) or, most interestingly, B27+ normal individuals 
(B27+ AS-) (181). Using these antisera, Geczy's group 
were able to distinguish between B27+ AS+ and B27+ AS- 
cells in two blind trials using cells supplied by a 
British (182) and a Dutch (115) group. Geczy et a l . (183)
showed that B27+ AS- cells could be made susceptible to 
lysis by anti-Klebsiella antisera by incubating them with 
the filtrates of culture supernatants from K43 but not 
other non "cross-reactive" serotypes of Klebsiella. The 
active factor, which they called "modifying factor", was
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found to be associated with Klebsiella outer membranes and 
had a molecular weight of approximately 30kD (184). Other 
enteric organisms including certain isolates of 
Salmonella, Shigella and E .coli were found to possess a 
similar activity (185) and the authors propose (46) that 
this modifying factor is encoded by plasmid genes.
Several investigators, however, have failed to find 
evidence to support the findings of either Geczy's or 
Ebringer's group. As far as it is known, only one other 
group has managed (after many unsuccesful attempts) to 
produce an anti-Klebsiella antiserum which can distinguish 
between B27+ and B27- cells (186). Beaulieu et a l . (47)
looked at 98 different antisera to various strains of 
Klebsiella including some raised against faecal isolates 
from AS patients and two raised against K43 and K21 
isolates provided by Geczy (which his group had found to 
give rise to antibodies cytotoxic for B27+ cells) . The 
antisera were tested using a chromium-release 
microcytotoxicity assay similar to that of Geczy's but 
none of them were found to be reactive with B27+ AS+ or 
B27+ AS- cells. Other groups, including our laboratory, 
have reported negative results with anti-Klebsiella 
antisera in the raicrocytotoxic assay (48, 49, 50) . Inman
et a l . (187) studied anti-Yersinia and anti-Chlamydia
antisera from both immunised rabbits and recently infected 
patients. Anti-bacterial antibodies from neither source 
were specifically cytotoxic for B27+ lymphocytes.
This cytotoxic assay only measures antibodies which fix 
complement and some cross-reactive antibodies may 
therefore go undetected. Georgopolous et a l . (188) used
an ELISA to study several anti-Klebsiella antisera 
including some raised against strains identical to Geczy's 
and "positive" antisera provided by both Geczy and 
Ebringer. They failed to find any evidence for cross- 
reactivity. Similar ELISA results were reported by Singh 
et al. (189).
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A more recent approach to the study of cross-reactivity 
between Klebsiella and B27 has involved the use of 
monoclonal antibodies. By immunoblotting, Ogasawara et 
al ♦ (43) demonstrated that an anti-B2 7 monoclonal antibody
reacted with 60kD and 80kD proteins of Klebsiella 
pneumoniae K43. No reactivity was observed when several 
other Gram-negative bacteria or a series of other 
monoclonal antibodies were used. An antiserum was raised 
to the 80kD protein and its reactivity to Klebsiella 
envelopes was partially inhibited by absorption with B27+ 
cells although it did not react with B27+ cells in a 
microcytotoxic assay. van Bohemen et a l . (190) reported
different results with the same monoclonal antibody - it 
was found to recognise a 20kD protein from Shigella but 
showed no reactivity to Klebsiella. Other monoclonal 
antibodies have been shown to have high reactivity to 
strains of Klebsiella (44), Yersinia (191) and Shigella 
(192) .
As well as the use of anti-B27 monoclonal antibodies,
monoclonal antibodies have been raised to arthritogenic 
bacteria and their reactivity to B27+ cells studied. Kono 
et a l . (193) demonstrated that a Yersinia-specific
monoclonal antibody reacted with 12/12 B27+ lymphoblastoid 
cell lines and only 4/31 B27- cell lines. (Three of the 
B2 7- lines which reacted with the monoclonal antibody were 
positive for B7, an HLA antigen which cross-reacts with
B 27.) A cell line which lost its expression of B27 
through mutation no longer reacted with the antibody.
These studies have investigated cross-reactions using 
purely immunological techniques. A more recent approach, 
made possible by the complete amino acid sequencing of the 
B27 antigen (194), has involved looking for amino acid 
sequence homology between B27 and bacterial proteins. As
well as providing support for the molecular mimicry theory
of AS, this approach could provide valuable information on 
which bacterial proteins might be involved.
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Schwimmbeck et a l . (45) used a computer search programme
to screen a major protein database (Dayhoff Database
(195)) for amino acid sequences shared between B27 and any 
other sequenced protein. They identified a stretch of six 
amino acids of the B27 allotype B27.1 - residues 72-77 -
that matched residues 188-193 of the nitrogenase enzyme of 
Klebsiella pneumoniae : Glutamine-Threonine-Aspartic acid- 
Arginine-Glutamic acid-Aspartic acid (QTDRED) The
authors claim that the probability of a hexamer occurring 
at random is 1:64 million. This sequence is localised in 
the hypervariable region of the B27.1 antigen and was not 
found in any of the other HLA antigens. Hydrophobicity 
plots revealed that the hexamer is hydrophilic and 
v therefore likely to be expressed on the surface of a 
molecule where it would be accessible to the immune 
system.
To determine whether this sequence homology reflected an 
immunological cross-reaction, the same group (196) made a 
series of synthetic peptides representing the hexamers 
together with flanking regions of various lengths : e.g.
AKAQTDREDLRTLLRY# representing residues 69-84 of B27.1, 
and NSRQTDREDELIGGC representing residues 185-196 of 
Klebsiella nitrogenase. Affinity purified antibodies to 
B27-peptides were shown to be reactive in an ELISA to 
Klebsiella-derived peptides.
Shwimmbeck et a l . (45) then looked for the presence of
antibodies to these synthetic peptides in the sera of 
patients with AS and RD. By ELISA, they found that 29% of 
AS patients and 53% of RD patients had significant levels 
of antibodies to a B27-derived peptide, and over 40% of 
both groups were found to possess antibodies reactive to a 
Klebsiella-peptide. Less than 5% of normal individuals 
had antibodies to either peptide.
Amino acid sequence homology with B27 is not confined to 
Klebsiella. In a recent study, Steiglitz et a l . (197)
screened a panel of Shigella strains and identified a 2
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megadalton plasmid specific for arthritogenic strains of 
the bacteria. The complete nucleotide sequence of the 
plasmid was determined and the amino acid sequence 
inferred from it was found to contain a pentamer 
homologous to residues 71-75 of B27.1 (AQTDR). This 
stretch of the B27 antigen clearly overlaps with the 
QTDRED hexamer shared with Klebsiella nitrogenase. It is 
not known whether patients with Shigella-arthritis possess 
antibodies to this pentamer.
6.2 Aims of Study
1) To measure the binding of anti-Klebsiella antisera to 
B27+ cells in an immunofluorescence assay.
2) To measure the binding of anti-B27 tissue-typing sera 
to Klebsiella in an ELISA.
3) To look for the presence of antibodies in patients' 
sera to a synthetic peptide representing a hexamer 
(QTDRED) shared by the B2 7 antigen and a Klebsiella 
protein.
6 ^ 3 ^ S u b j e c t s a n d M e t h o d s
6.3.1 Measurement of anti-B27 reactivity of anti-
Klebsiella antisera.
Anti-Klebsiella antisera
Three rabbit antisera specific for Klebsiella pneumoniae 
K43 were used - the two described in Section 5.3.3 and 
another previously prepared in our laboratory. An 
antiserum specific for Klebsiella pneumoniae K21 was 
provided by Tyrone Pitt (Central Public Health Laboratory, 
Colindale) and a non-immune rabbit serum was also studied. 
The reactivity of the antisera to Klebsiella was tested in 
an ELISA as described in Section 3.3.2 except that a
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1:1000 dilution of biotinylated anti-rabbit immunoglobulin 
was used as the second antibody.
Immunofluorescence assay
Lymphocytes were isolated from peripheral blood and stored 
in liquid nitrogen as previously described (Section 2.3.2 
and 4.3.1). On the day of the assay, the cells were 
thawed and washed three times in RPMI 1640 medium by 
spinning at 250g for 10 minutes. They were counted in 
0.05% trypan blue in an Improved Neubauer Chamber and 
adjusted to a concentration of 5x107 cells/ml in RPMI 
containing 0.1% sodium azide and 0.1% HSA (incubation 
medium). 10|xl of cells were added to the wells of a 96- 
well round-bottom plate (Corning, UK). 100|il of the 
rabbit test sera or 50|il of a 1:25 dilution of an anti-B27 
monoclonal antibody (Serotec, UK) in incubation buffer 
were added and the cell suspension was carefully mixed. 
The plate was left at room temperature for 45 minutes. 
100^1 of cold incubation medium were added to each well 
and the plate spun at 250g for 10 minutes at 4°C. The 
supernatant was aspirated and the pellets were resuspended 
in 200|il medium and washed twice more in the same way. 
The cells were then resuspended in 50|il of a 1:30 dilution 
of fluorescein-labelled swine anti-rabbit immunoglobulins 
(Dakopatts, Denmark) or a 1:50 dilution of fluorescein- 
labelled sheep anti-mouse IgG (SAPU, Scotland) in 
incubation buffer and left at room temperature for 45 
minutes. 150^1 of cold incubation medium were added to 
each well and the cells washed as before. The pellets 
were resuspended in 10^1 of cold PBS then transferred to 
pre-washed glass microscope slides (Chance Propper, UK) 
and covered with a glass coverslip (Chance Propper, UK).
The cells were viewed under a fluorescence microscope 
(Leitz Wetzlar, Germany). The total number of cells in 
one field of view was counted under normal light and the 
number of these cells which were peripherally stained with 
fluorescence was counted under U.V. light. Several fields
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of view were selected until at least 100 cells had been 
counted. The number of fluorescently stained cells was 
expressed as a percentage of the total number of cells 
after the background had been subtracted (the percentage 
of cells stained in the presence of fluorescein-labelled 
second antibody only).
6.3.2 Measurement of anti-Klebsiella reactivity of anti- 
B27 tissue-typing sera
Sera
Human tissue - typing sera were kindly donated by the UK 
Transplant Service (Bristol). Three anti-B27 antisera, 
two anti-B14 antisera and one antiserum of each of the 
following HLA specificities were supplied : B8, B13, B16, 
B17, A1 , A2 and A3. Each of these had been obtained from 
a single pregnant woman. In addition, two commercially 
available anti-B27 sera and an anti-B5 antiserum 
(Behring, UK) were used. Each antiserum was known to be 
reactive to their corresponding HLA antigen in the 
microcytotoxicity assay.
ELISA
An ELISA of antibodies to formalin-killed and sonicated 
Klebsiella and E .coli was carried out as previously 
described for patient sera (Section 3.3.2).
6.3.3 Measurement of antibodies to the peptide QTDRED in 
patients1 sera
Subjects
Patients with inactive disease (IA), patients with active 
disease (A) and controls (C) were studied. The details 
are given over the page.
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c IA A
Number 19 15 15
Mean age in years 
(Range)
33
(23-50) (26-71)
49 45
(26-64)
Male:Female ratio 3.2:1 6.5:1 6.5:1
Peptide Synthesis
The amino acid hexamer QTDRED (Glutamine-Threonine - 
Aspartic acid-Arginine-Glutamic acid-Aspartic acid) was 
synthesised for us by BioMac/ UK using a Biosearch 9500 
automatic synthesiser and purified using reverse-phase 
HPLC. The molecular weight of 762g/mol was confirmed by 
FAB-mass spectrometry.
Preparation of peptide-HSA conjugate
The peptide was conjugated to HSA at a peptide:protein 
ratio of 40:1 using the gluteraldehyde coupling method 
(198). A 1mg/ml solution of the peptide and a 2. 2mg/ml 
solution of HSA were made up in PBS and 1ml of each 
solution were mixed. 2ml of 1% gluteraldehyde in PBS were 
added and the mixture stirred overnight at 4°C. The 
solution was then dialysed against PBS to remove the 
gluteraldehyde.
ELISA
a) Unconjugated peptide
The ELISA plates were pre-coated with poly-L-lysine (PLL) 
to enhance the binding of the peptide : 100|il of a 20mg/ml 
solution of PLL (Sigma, U.K.) were added to the wells and 
the plates incubated at 37°C for 1 hour. The plates were 
washed twice in PBS then coated with 100^1 of a 200^g/ml 
solution of the peptide in PBS. The assay was carried out
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as described for total antibodies to bacteria (Section 
3.4.1).
b) Peptide-HSA conjugate
Wells were coated with lOOjil of an 8.9^g/ml solution of 
HSA conjugated to peptide (4^ig/ml peptide) or 8.9|ig/ml HSA 
alone in 50mM carbonate buffer (pH9.6). The assay was 
carried out as described for total antibodies to bacteria 
(Section 3.4.1). The absorbance (405nm) readings obtained 
with HSA alone were subtracted from the readings obtained 
with the peptide-HSA conjugate.
6.3.4 Statistical Analysis
The Mann-Whitney test was used (see Appendix B ) .
6^ 4Results
6.4.1 Measurement of anti-B27 reactivity of anti-
Klebsiella antisera
Demonstration of B27 on surface of cells using a 
monoclonal antibody
The reactivity of an anti-B27 monoclonal antibody to 
lymphocytes from three B27+ and three B27- individuals was 
studied. The mean (+ SEM) percentage of B2 7+ and B2 7- 
cells which were fluorescently stained was 97.3 (+1.3) %
and 12.3 ( + 2.3) % respectively. This demonstrates that
anti-B27 reactivity can be detected using this 
immunofluorescence assay.
Reactivity of rabbit anti-Klebsiella antisera to 
Klebsiella
The reactivity of the rabbit anti-Klebsiella antisera to 
Klebsiella was confirmed by an ELISA. When tested against 
the K43 serotype, 1:1000 dilutions of the three anti-K43 
antisera gave absorbance (405nm) readings of 0.86, 0.78
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and 0.69. The anti-K21 antiserum gave an absorbance
(405nm) reading of 0.85 in an ELISA with K21 . This shows 
that the four antisera contain high levels of anti- 
Klebsiella antibodies. The non-immune rabbit serum did 
not contain significant levels of such antibodies : a
1:1000 dilution gave an absorbance (405nm) reading of 
< 0.02 in response t o ,Klebsiella of either serotype.
Binding of anti-Klebsiella antisera to B27+ cells
a) Effect of antiserum dilution
Figure XXV shows the level of immunofluorescent staining 
found when lymphocytes from a B2 7+ individual are 
incubated with various concentrations of anti-Klebsiella 
antisera : 1:2, 1:4, 1:8, 1:16 and 1:64 dilutions. There
is clearly significant binding of antibodies to the cells 
at high serum concentrations, with a negligible response
at a 1:64 dilution. This was repeated with cells from two
other B27+ individuals and a similar pattern was obtained. 
A 1:4 dilution of each antiserum was used for comparing 
B27+ and B27- cells since this dilution lay within the 
linear part of the curve.
b) Comparing B27+ and B27- cells
To see if the reactivity of the anti-Klebsiella antisera
to B27+ cells was any higher than that to B27- cells, a
1:4 dilution of each antiserum was tested against cells 
from 10 B27+ individuals (V B27+ AS+ and 3 B27+ AS-) and 
10 B27- individuals. The results are shown in Figure
XXVI. There was no significant difference in the binding 
to B27 + and B27- cells for any of the four antisera.
c) Comparing immune and non-immune sera
The binding of a non-immune serum to cells from five B27 + 
individuals was measured. The median percentage of
fluorescently stained cells was 22.5% (interquartile range 
= 18.4 - 27.4%) and this was similar to that found with
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the corresponding immune serum (median = 19.2%,
interquartile range = 12 - 26.6%).
6.4.2 Measurement of anti-Klebsiella reactivity of anti- 
B27 tissue-typing sera
Comparing anti-B27 and other tissue-typing sera
The binding of five anti-B27 tissue-typing sera and ten 
antisera of other HLA specificities to formalin-killed and 
sonicated Klebsiella was studied in an ELISA. 1:10, 1:100 
and 1:500 dilutions of each antiserum were tested and the 
results are shown in Figures XVII and XVIII. The anti-B27 
antisera did not show higher binding than the non-B27 
antisera to either preparation of Klebsiella at any of the 
dilutions studied.
Comparing Klebsiella and E.coli
The binding of each anti-B27 antiserum to E .coli was also 
studied and was found not to be significantly different 
from the level of binding to Klebsiella. This was true 
for each antiserum dilution studied and when either 
formalin-killed or sonicated bacteria were used.
6.4.3 Measurement of antibodies to the peptide QTDRED in 
patients' sera
Unconjugated peptide
An ELISA was used to look for antibodies to the 
unconjugated peptide QTDRED in the sera of ten patients 
and ten controls. A 1:10 serum dilution was used. All 
absorbance (405nm) readings were below 0.1, indicating a 
negligible response.
An antiserum to the peptide which had been raised in our 
laboratory and which was known to contain high levels of 
peptide - specific antibodies (see next section) also gave 
absorbance readings of below 0.1. This suggests that this
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ELISA system with unconjugated peptide is inefficient at 
detecting anti-peptide antibodies.
Peptide-HSA conjugate
With HSA alone as the blank, the reactivity of the anti- 
peptide rabbit antiserum to the peptide-HSA conjugate was 
measured by ELISA. A 1:1000 dilution gave an absorbance 
(405nm) reading of around 1.0 (compared to < 0.1 for the 
pre-immune serum). This indicates that peptide-specific 
antibodies can be detected using this conjugated peptide 
ELISA.
Using this system, the presence of antibodies to the 
peptide was studied in the sera of 19 controls, 15 
patients with inactive disease and 15 patients with active 
disease. As expected, the absorbance (405nm) values
obtained when wells were coated with the human protein HSA 
alone were very similar to that of uncoated wells. Figure 
XXIX shows the absorbance (405nm) readings obtained with 
the peptide-HSA conjugate and a 1:10 dilution of sera. In 
each subject group, the median absorbance value is below 
0.1, indicating a very low level of antibodies to the 
peptide. When the three groups were compared, no
significant difference was found. 1:50 and 1:100 serum 
dilutions were also studied and there was again no 
difference between the groups.
Discussion
This study investigated the possibility of cross-reaction 
between the HLA-B27 protein and Klebsiella antigens by 
measuring the reactivity of anti-Klebsiella antisera to 
B27+ cells and the ability of anti-B27 antisera to bind to 
Klebsiella.
Using an immunofluorescence assay, we measured the anti- 
B27 reactivity of four rabbit antisera raised against 
Klebsiella pneumoniae K43 or K21, bacteria which have been
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implicated in AS. As far as we know, this is the only 
reported study which has used immunofluorescence to look 
at this. Each antiserum demonstrated significant binding 
to B27+ lymphocytes but this was no higher than that found 
to B27- cells. Moreover, a non-immune rabbit serum
showed a similar level of binding. The observed
reactivity seems, therefore, to be independent of the B27 
antigen and anti-Klebsiella antibodies. It may be
attributable to an antibody response to any number of 
cell-surface antigens. This is a problem with studies
such as this : rabbit serum antibodies may recognise
commonly found cell-associated antigens which could mask 
any specific response to B27. Nevertheless, Geczy and
Ebringer have both been able to demonstrate a selective
binding of rabbit anti-Klebsiella antisera to B27+ cells. 
Like us, several groups have failed to confirm their
findings (47, 48, 49, 188).
Most of the cross-rectivity studies have employed 
microcytotoxic assays. It is not clear why such 
conflicting results have been obtained with this assay. 
Beukelman et a l . (186) suggest that the use of different
bacterial, strains, experimental animals and immunisation 
procedures may account for the inability of other 
investigators to reproduce Geczy's or Ebringer's results 
but the negative findings reported with Geczy's bacterial 
isolates (47) and with antisera from Geczy and Ebringer 
(188) do not support this explanation.
Even if the findings of Geczy's or Ebringer's group were 
confirmed by other investigators, to convince us that 
anti-Klebsiella antibodies are reactive to the B27 antigen 
requires more than simply demonstrating that anti- 
Klebsiella antisera bind to B27+ cells more readily than 
B27- cells. For example, neither of the two groups have 
described whether this binding is blocked by polyclonal or 
monoclonal anti-B27 antibodies.
99
We also studied cross-reactivity between B27 and
Klebsiella by measuring the ability of human tissue-typing
sera to bind to Klebsiella. Using an ELISA, we found no
evidence that anti-B27 tissue-typing sera were more
reactive than non-B27 antisera to either formalin-killed
or sonicated Klebsiella. Moreover, the anti-B27 antisera
showed no more reactivity to Klebsiella than to E .coli, a
bacterium which is not thought to cross-react with B27.
This contrasts with the findings of Avakian et a l . (42)
who used three assay systems to show that anti-B27 tissue-
typing sera were more reactive than non-B27 antisera to
Klebsiella. The use of a different assay or a smaller
number of antisera in our study may, in part, account for
these different findings. However, in Avakian's study,
the differences observed in the reactivity of anti-B27 and
non-B27 sera to Klebsiella were not large. In their
competition assay, they measured the ability of tissue-
typing sera to inhibit the binding of anti-Klebsiella
antisera to Klebsiella. The mean level of inhibition
shown by the anti-B27 antisera was around 85% and the non-
B27 antisera produced 70% inhibition. While this
difference may be statistically significant, it does not
provide convincing evidence that anti-B27 antibodies bind
to Klebsiella. In the direct binding experiments, the 
-----------
difference in the percentage of radiolabelled Klebsiella 
sonicates bound by anti-B27 and non-B27 antisera was an 
equally unimpressive 5%.
One of the problems with studies like these is the high 
background level of antibodies to Klebsiella found : most 
individuals possess a significant level of antibodies 
which bind to Enterobacteriaceae (see Chapter 3) and it is 
possible that any response mediated by anti-B27 antibodies 
is masked. This is why many recent studies have employed 
monoclonal antibodies and these have provided some 
evidence for cross-reaction between B27 and certain 
Enterobacteriaceae. However, conflicting data have been 
reported on the reactivity of anti-B27 monoclonal 
antibodies to Klebsiella (43, 44) and two studies (44,
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191) demonstrated high reactivity of such antibodies to 
strains of E . coli, a bacterium which has not been 
associated with the seronegative spondyloarthropathies. 
Moreover, monoclonal antibodies react with a single 
epitope and any cross-reactive epitope identified may be 
of little importance in the normal immune response to the 
antigen. The molecular mimicry theory of AS is dependent 
on the ability of the immune response to the bacteria 
induced in patients to cross-react with the B2 7 antigen.
Recent studies have been involved in looking for a 
molecular basis for cross-reaction between B27 and 
Klebsiella. Schwimmbeck et a l . (196) identified a stretch
of six amino acids (QTDRED) found in both the B27.1 
protein and a Klebsiella nitrogenase and they were able to 
demonstrate high levels of antibodies to peptides 
containing this hexamer in the sera of patients with AS. 
In an attempt to confirm their findings, we used an ELISA 
to measure serum antibodies to a synthetic peptide 
representing this six amino acid sequence.
Initially, unconjugated peptide was used as in 
Schwimmbeck's study but this ELISA was unable to detect 
specific antibodies in an anti-peptide antiserum. This is 
most likely because we used a much smaller peptide and
small peptides do not bind well to ELISA plates (198). We 
then conjugated the peptide to HSA, a protein which human 
serum antibodies do not recognise. Using this in the
ELISA, we were able to demonstrate high levels of anti- 
peptide antibodies in the rabbit antiserum and this system 
was therefore used to study sera from patients. Very low 
levels of anti-peptide antibodies were found and there was 
no difference between patients and controls. This 
contrasts with the high ELISA readings found by
Schwimmbeck et a l . (196) (median absorbance values of
around 1.0 compared to < 0.1 for the same serum dilution 
in our study) . This difference is probably due to the
size of the peptides used. They used peptides of 13-16 
residues representing the homologous hexamer together with
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flanking residues normally found in the B2 7 or Klebsiella
protein. It is clear that our peptide, which consisted of
the hexamer only, is immunogenic since we were able to
raise an antiserum to it, but the epitope formed may be
very different from that found when the peptide is part of
a large stretch of amino acids. The flanking residues can
strongly influence the three-dimensional structure of the
peptide. It is probable that the shape of the hexamer
used in Schwimmbeck's study resembles the epitope of the
native protein more than does our peptide and this could
explain our inability to detect antibodies in patients'
/
sera. A larger peptide should perhaps have been used in 
our study.
The findings of Schwimmbeck's group have stimulated a 
great deal of interest but their proposal that the 
antibody response to this homologous sequence has a 
pathogenic role in AS is questioned for a number of
reasons. (1) The evidence that peptides derived from B27 
cross-react with Klebsiella-derived peptides is not 
convincing : while two of Schwimmbeck's anti-B27 peptide 
antisera bound well to a Klebsiella-derived peptide (196, 
199), another showed very little response and both 
antisera raised to Klebsiella-peptides had little or no
reactivity to a B27-peptide. (2) There is no reported 
evidence that cross-reactivity between these peptides 
occurs at the protein level : in a 1988 review,
Schwimmbeck et a l . (200) claim that anti-peptide
antibodies are cytolytic for B27+ cells and bind to 
isolated Klebsiella nitrogenase but as far as we know, the 
details of this study have never been published. (3) The 
QTDRED hexamer is found in the B27.1 allotype only but all 
six variants of B27 are associated with AS (30) . (4) In
their search for shared sequences, Schwimmbeck et a l .
(196) found " several homologies between HLA-B27 and 
microbes ". The " best fit " was with Klebsiella 
nitrogenase but this may be no more relevant than, say, a 
five amino acid sequence shared with some virus. Peptides 
representing some of the other homologous regions would
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serve as useful controls in studies of anti-peptide 
antibodies in patients. No peptide controls were used in 
Schwimmbeck's study. (5) Klebsiella nitrogenase is 
unlikely to be of importance in AS : the gene for this
enzyme is normally only expressed in nitrogen-free 
environments and should therefore be suppressed in a human 
host.
This sequence homology between B27 and a Klebsiella 
protein may be purely coincidental. Many such homologies 
exist between disparate proteins (201). An eight amino 
acid sequence common to IgG and HIV has been identified 
and there has been no claim that this has any pathogenic 
significance.
Numerous studies have investigated the possibility that
B27 cross-reacts with Klebsiella or other 
Enterobacteriaceae but one question which is central to
the molecular mimicry theory of AS is often ignored : do 
patients show any evidence of an autoimmune response to 
the B27 antigen? Two groups (202, 203) have looked for
antibodies directed against B27+ cells in the sera of 
patients and none were found. It is of course possible 
that anti-B27 autoimmunity is mediated, not by antibodies, 
but by T-cells, but no evidence for this has been
reported.
In conclusion, although the molecular mimicry theory of AS 
is an attractive theory which has stimulated much interest 
over the last decade, the evidence for it is not 
convincing and the findings of ours and many other studies 
fail to support it.
103
C H A P T E R  7
DISCUSSION
For more than a decade, there has been much interest in the 
theory that Klebsiella or other Enterobacteriaceae play a 
pathogenic role in AS through molecular mimicry with the 
B27 antigen. So, what is the evidence to support such a 
proposal?
1) Reports that patients have a high faecal carriage rate 
of Klebsiella
These reports are controversial : several investigators
(54, 55, 56) have failed to support the findings of
Ebringer's group (41, 51). Using rectal swabs, we isolated 
Klebsiella from only 17% of patients with AS and found no 
difference between patients with active disease and those 
with inactive disease. Moreover, none of the Klebsiella 
isolate^d were K43 - the serotype most strongly implicated 
in AS (43, 46) . The molecular mimicry theory of AS does
not, however, rely on the constant presence of Klebsiella 
in the bowel : the bacterium could stimulate an immune
response which is continued because of the presence of the 
cross-reactive B27 antigen.
2) Reports that patients have elevated levels of IgA 
antibodies to Klebsiella or other Enterobacteriaceae
Although higher than normal levels of bacterial- specific 
IgA antibodies in patients' sera have been demonstrated in 
this and other studies (39, 67, 69), their significance is 
far from clear. In many cases, the differences observed 
between patients and contols, although statistically 
significant, are not marked. Most individuals already 
possess significant levels of antibodies which react with 
Enterobacteriaceae and it is not clear how meaningful small 
increases in these levels are. Moreover, there is much
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controversy over exactly which anti-bacterial antibodies 
are raised. Some studies have demonstrated elevated IgA 
antibodies to Klebsiella only (39,67), another found raised 
IgA antibodies to Yersinia only (69), and our study 
demonstrated high levels of antibodies to Yersinia and 
Shigella which were associated with active disease and 
raised antibodies to Klebsiella and Salmonella which were 
independent of disease activity. A varied assortment of 
"control" organisms have been used in different studies - 
even in studies by the same group.
It is by no means clear that these raised anti-bacterial 
antibodies are unique to AS patients. Although Ebringer's 
group have found a normal anti-Klebsiella antibody response 
in patients with other inflammatory diseases such as RA and 
PsA (52), one study has demonstrated high serum levels of 
antibodies to Klebsiella in patients with RA (123) and, 
most interestingly, such antibodies have been found to be 
raised in inflammatory bowel disease (103, 123). It is
suggested that this could be due to an abnormal bowel 
permeability in such patients. Increased bowel permebility 
has been reported in AS (124) and this was supported by a 
recent study of 17 of our patients (207). Studies by 
Bjarnasson et a l . (125) and Jenkins et a l . (126) suggest 
that NSAID treatment may be responsible for this. It is 
possible that increased bowel permeability allows the 
transfer of normally excluded bacterial antigens across the 
intestinal mucosa into the circulation where they induce a 
systemic immune response. Thus, the high anti-bacterial 
antibody levels found in AS may have no pathogenic 
significance but could simply be a consequence of therapy. 
In a study soon to be carried out in our labaratory, the 
level of anti-bacterial antibodies in healthy volunteers 
receiving NSAIDs will be compared to those of healthy 
controls.
Although AS patients have elevated antibodies to gut 
bacteria in their serum, there is little evidence of 
antigenic stimulation of the gut itself. Trull et a l . (65)
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demonstrated high levels of anti-Klebsiella antibodies in 
patients' saliva but our study and that of Pease et a l .
(69) showed no difference between patients and controls in 
the level of salivary antibodies to either Klebsiella or 
Yersinia. It could be argued that salivary antibodies do 
not provide a good indication of the intestinal immune 
response (97, 102) but in a recent study, anti-Klebsiella
antibodies were measured in gut lavage fluid and the levels 
found in AS patients were no higher than in contols (103).
If antibodies to Klebsiella or other Enterobacteriaceae 
played any pathogenic role in AS, we would expect to find 
them at the site of disease - the joints. We found that 
the antibody levels to several bacteria in the synovial 
fluids of AS patients were no higher than those found in 
synovial fluids from patients with RA or one of a variety 
of other inflammatory joint diseases. Moreover, in
reactive arthritis, the cellular immune response to the
causative organism is markedly elevated within the joint 
(137, 140) but we found no evidence that synovial
lymphocytes from AS patients make a high proliferative 
response to Klebsiella.
3) Reports of cross-reaction between Klebsiella and the B27 
antigen
The main theory proposed to explain the involvement of 
bacteria in AS is that of molecular mimicry with the B27
antigen but the subject of cross-reaction between
Klebsiella and B27 is one of much controversy. Several
#■11 ■ ' " ' i '
investigators (47, 48, 49, 50) have failed to support the
findings of either Ebringer's (25) or Geczy's (46) groups. 
A large number of these studies have relied on measuring 
the reactivity of anti-Klebsiella antisera to B27+ cells in 
a microcytotoxic assay. Using an immunofluorescence 
method, we found that anti-Klebsiella antisera were no more 
reactive to B27+ lymphocytes than to B27- cells. We also 
measured the ability of several human tissue-typing sera to 
bind to Klebsiella and other Enterobacteriaceae in an
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ELISA. Anti-B2 7 sera showed no more reactivity than 
tissue-typing sera of other specificities. These studies 
which involve comparing B27+ and B27- cells or B27 and non- 
B2 7 antisera have obvious problems with high backgrounds 
and more sophisticated methods are clearly required. 
Ideally, purified B27 antigen and isolated Klebsiella 
proteins should be studied but these would be difficult to 
prepare. More practical approaches are possible : e.g. if, 
by running B27+ cells on a gel and immunoblotting with 
anti-B27 monoclonal antibodies, the bands representing the 
B27 antigen could be identified, we could study the 
reactivity of purified polyclonal or monoclonal anti- 
Klebsiella antibodies to these bands.
One group sought a possible molecular basis for cross- 
reactivity between B27 and Klebsiella and identified a six 
amino acid sequence shared by the B27 antigen and a 
Klebsiella nitrogenase (45) . However, there is no evidence 
that this sequence homology reflects an immunological 
cross-reaction at the protein level.
Even if cross-reaction between Klebsiella and B27 could be 
proven beyond doubt, it might have no pathogenic 
significance. Other examples of cross-reactivity between 
gut bacteria and human cell surface antigens have been 
demonstrated - e.g. between E .coli and ABO blood group 
antigens of human erythrocytes (204) and as far as it is 
known, these cross-reactions have no pathogenic 
consequences.
Thus, the evidence supporting the proposal that 
Enterobacteriaceae play a role in AS is, at best, 
unconvincing. In addition, there are certain fundamental 
problems with the theory that molecular mimicry between 
bacteria and the B27 antigen leads to tissue damage. 
Firstly, the B27 antigen is found on all nucleated cells, 
so why should the inflammation in AS be restricted to the 
joints and a few other isolated sites? Secondly, there is
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no evidence that patients express an anti-B27 response. As 
far as we know, only two reported studies (202, 203) have 
looked for anti-B27 antibodies in patients' sera (where 
none were found), and the presence of such antibodies in 
the joints has not been investigated.
It is possible that Enterobacteriaceae could play a more 
direct role in the disease - e.g. bacterial antigens may be 
present in the joint where they induce an immune response 
which causes damage to surrounding tissue. This could be 
the case in the known reactive arthritides where there is 
increasing evidence for the presence of bacterial antigens 
(36, 64) and a bacterial-specific cellular immune response 
(137, 140 in the joints. However, we failed to detect a
humoral or cellular response to Klebsiella in the joints of 
patients with AS. A search for bacterial antigens within 
AS joints is needed and immunohistochemical studies of 
synovial tissue are underway in our laboratory. (The 
availability of such tissue from AS patients is, however, 
limited.) A useful approach to the identification of any 
environmental agents in AS may be the study of antigens 
within patients' immune complexes. By running crude 
preparations of immune complexes (PEG precipitates) on SDS- 
polyacrylamide gels and immunoblotting with anti-Klebsiella 
antisera, we found no evidence for the presence of 
Klebsiella antigens within immune complexes from patients' 
sera or synovial fluid. However, further studies are 
required - e.g. purified immune complexes could be 
dissociated into antigen and antibody components and the 
reactivity of these components studied by ELISA and 
immunoblotting.
At present, the evidence that Enterobacteriaceae play a 
role in AS is far from convincing and the results of this 
study have failed to support such a proposal.
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Appendix A
POINT SYSTEM FOR ASSESSMENT OF DISEASE ACTIVITY
Use of NSAIDs
None
Regular
Peripheral
None
Previous
Current
ESR 
< 30 
30-60 
> 60
= 0 
=  1
arthritis 
= 0 
=  1 
=  2
= 0 
=  1 
=  2
Morning Stiffness 
None = 0
< 1 hour = 1
> 1 hour = 2
CRP levels 
< 1 0  = 0
10-50 = 1
> 5 0  = 2
Immunoglobulin levels
Normal (IgG = < 15mg/ml; IgA = £ 4.5mg/ml) = 0
Elevated (IgG = > 15mg/ml or IgA = > 4.5mg/ml) = 1
NSAIDs = Non-steroidal anti-inflammatory drugs
CRP = C-reactive protein
ESR = Erythrocyte sedimentation xate
Patients with < 5 points are considered to have inactive 
disease
Patients with > 5 points are considered to have active 
disease
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Appendix B 
STATISTICAL ANALYSIS
The main statistical test used in this study was the Mann- 
Whitney U-test for the comparison of two samples. This is 
a non-parametric method which can be used to analyse data 
which is not normally distributed. Spearmann-rank and 
chi-squared tests were also used. All tests were performed 
on an Amstrad PC 1640 computer using a Statgraphics package 
(version 2.6). For formulae and detailed descriptions of 
each test, see Bailey (208).
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